Teses / dissertações: "HIV/Hepatitis C"

1

Mohsen, Abdul Hadi. "The epidemiology of hepatitis C and HCV-HIV coinfection". Thesis, King's College London (University of London), 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.424448.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Falconer, Karolin. "HIV-1/HCV co-infection immunity and viral dynamics /". Stockholm, 2010. http://diss.kib.ki.se/2010/978-91-7409-762-7/.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Yuen, King-tai, e 袁敬弟. "A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/193555.

Texto completo da fonte

Resumo:

The cost effectiveness of using novel HCV treatment option, telaprevir and boceprevir, should depend on patients’ respond to conventional PEG-INFα and ribavirin therapy. The study of pharmacogenomics, interleukin-28B (IL-28B) polymorphisms, accompanied with the information of HCV genotypes are suggested to have the strongest predictive value of treatment outcomes and prognosis of disease in individuals infected with HCV who are undergoing conventional PEG-INFα and ribavirin therapy. It is extremely valuable in HCV/HIV co-infected patients as these groups of patients require a complex treatment regimen and demonstrate poor sustained viral response (SVR) rate. The development of a fast and promising IL-28B genotyping assay is urgently needed. A total of 47 blood samples randomly selected from HCV and HIV co-infected patients were used in this investigation. The aims of this study are to evaluate and compare the performance of newly developed IL-28B HybProbe real-time PCR assay using LightCycler® system against Sanger Sequencing method in determining IL-28B polymorphisms on rs12979860 and rs8099917 and to estimate the prevalence of IL-28B polymorphisms among HCV/HIV co-infected patients in Hong Kong. In addition, the genotypic distribution of HCV among the same patient group is identified by using in-house Sanger Sequencing method. It was found that the newly developed IL-28B real-time HybProbe assay resulted in 100% concordance with the traditionally used Sanger Sequencing method. The allele frequencies of C and T were 96% and 4% in rs12979860 and T and G were 97% and 3% in rs8099917 respectively. The CC and TT wild type are predominating in rs12979860 and rs8099917 with frequencies of 93.62% and 95.74% respectively. The most favorable compound genotype CC/TT with both homozygous wild types on both SNPs was the most predominant type with a high prevalence of 93.61%. Among all the samples, 50% samples were found to be HCV genotype 1, 41.18% were genotype 6 and 8.82% were genotype 3. A simple and efficient IL-28B real-time HybProbe assay was developed in this study and proved to show excellent performance on IL-28B genotyping although further optimization is suggested before it can be applied in the clinical setting. The favourable wild type genotypes of rs12979860 and rs8099917 accounted for the most predominant genotypes which is similar to other findings obtained from an Asian population. A comparatively high prevalence of HCV genotype 6 was found in the HCV/HIV co-infected group. Future study with the information of treatment outcomes (HCV viral load) can further evaluate the predictive value of IL-28B polymorphisms on SVR in different HCV genotypes.
published_or_final_version
Medical Sciences
Master
Master of Medical Sciences

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Fialho, Renata. "Neuropsychiatric manifestations of hepatitis C treatment in HIV/HCV co-infection". Thesis, University of Sussex, 2017. http://sro.sussex.ac.uk/id/eprint/71260/.

Texto completo da fonte

Resumo:

Hepatitis C (HCV) infection is associated with high rates of mortality and morbidity. Interferon alpha based treatment for HCV offers a good rate of viral clearance, however the associated neuropsychiatric side effects increase the risk of treatment interruption and disease progression. The HIV/HCV coinfection is of particular interest due to association with higher rates of HCV treatment side effects and earlier treatment discontinuation when compared with HCV mono-infection. Therefore, the aim of the thesis was to further explore the effect of coinfection on mood and cognition and how HCV interferon based treatment influences neuropsychiatric side effects in mono and co-infected samples. Firstly a meta-analysis was performed to explore cognitive impairment and depression in HIV HCV co-infection. The results suggested that there was consistent literature indicating that the coinfected group were more cognitively impaired and more likely to be depressed than the HCV and HIV monoinfected groups. Secondly empirical studies were conducted to analyse the profile of depression during interferon-based treatment, and explore potential risk factors, such as gender and immune profile. Co-infected patients appeared less vulnerable to the emergence of depressive symptoms during HCV treatment than HCV mono-infected patients. Additionally, neither female gender nor immune response were associated with increased vulnerability to depression. Finally, a longitudinal study investigating cognitive performance during interferon-based treatment was conducted. A significant effect of treatment on information processing speed level of executive function was observed. Overall the research reported in this thesis further clarifies the nature of interferon induced depression and cognitive effects differences between mono and coinfected groups. Having identified a neurovegetative symptom profile and speed of processing impairment of executive function during HCV treatment, the discussion considers the potential of targeted interventions via psychotropic medication and cognitive interventions to minimise the impact of these treatment effects and optimise outcomes in this clinical group.

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Bertol, Bruna Cristina. "Expressão da molécula HLA-G e polimorfismos da região codificadora do gene HLA-G em pacientes infectados pelo vírus da hepatite C (HCV) apresentando ou não a coinfecção pelo vírus da imunodeficiência humana (HIV)". Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/17/17147/tde-10012017-112046/.

Texto completo da fonte

Resumo:

A hepatite C, causada pelo vírus da hepatite C (HCV), afeta milhões de pessoas no mundo. A transmissão do HCV é semelhante ao HIV, justificando a alta taxa de prevalência da coinfecção. Pacientes coinfectados HCV/HIV apresentam maior taxa de progressão da fibrose hepática e da mortalidade, em comparação aos pacientes monoinfectados com HCV. Assim, o estudo de genes e/ou moléculas que controlam a resposta imune é pertinente. No presente estudo, avaliamos o papel do antígeno leucocitário humano G (HLA-G), molécula com reconhecida atividade imunomoduladora, capaz de inibir a ativação das células T e a atividade citotóxica das células Natural Killers (NK) e linfócitos T CD8+, além de induzir a formação células T reguladoras. Nós investigamos 216 pacientes monoinfectados pelo HCV, 135 pacientes coinfectados HCV-HIV e 152 indivíduos não infectados. A variabilidade do gene HLA-G foi avaliada por sequenciamento de Sanger e a expressão hepática da molécula por imunoistoquímica. A expressão de HLA-G foi observada somente no tecido hepático dos pacientes, principalmente nos hepatócitos. O aumento de expressão de HLA-G foi associado com avanço da fibrose e da atividade necroinflamatória no fígado de ambos os grupos de pacientes. Idade igual ou superior a 40 anos e a cor de pele não-branca também foram associados com aumento da expressão hepática da molécula nos pacientes HCV. Outros fatores do hospedeiro analisados como gênero e genótipo do HCV não foram associados com o nível de expressão de HLA-G no fígado. A frequência do alelo HLA-G*01:01:01:01 estava aumentada nos pacientes HCV e do alelo G*01:05N diminuída nos pacientes coinfectados HCV-HIV, porém, não houveram associações significantes entre a variabilidade genética de HLA-G e a expressão hepática de HLA-G. O presente estudo contribui para a ampliar os conhecimentos acerca da participação da molécula HLA-G na hepatite C crônica, associado ou não com infecção pelo HIV.
Hepatitis C, caused by the hepatitis C virus (HCV), affects millions of people worldwide. The transmission of HCV is similar to HIV, which explains the high prevalence of coinfection. HCV-HIV coinfected patients have higher rate of liver fibrosis progression and mortality when compared to HCV monoinfected patients. Thus, the study of genes and/or molecules that control the immune response is relevant. In the present study, we evaluated the role of human leukocyte antigen G (HLA-G), a molecule known by its immunomodulatory activity, which is capable to inhibit T cell activation and cytotoxic activity of natural killer (NK) cells and CD8+ T cells, in addition to inducing the formation of regulatory T cells. We studied 216 HCV patients, 135 HIV-HCV coinfected patients and 152 uninfected individual. The variability of the HLA-G gene was evaluated by Sanger sequencing and the hepatic expression of the molecule by immunohistochemistry. The HLA-G expression was observed only in liver tissue of patients, mainly in hepatocytes. The increased HLA-G expression was associated with increased liver fibrosis and necroinflammatory activity in both groups of patients. The age greater than or equal to 40 years and the non-white skin color were also associated with increased hepatic expression of the molecule in the HCV patients. Other host factors analyzed as gender and HCV genotype were not associated with the level of HLA-G expression in the liver. The frequency of HLA-G*01:01:01:01 allele was increased in HCV patients and G*01:05N decreased in HCV-HIV coinfected patients, however, there was no significant association between the genetic variability of HLA-G and HLA-G liver expression. The present study contributes to expand the knowledge regarding the participation of HLA-G in chronic C hepatitis, associated or not with the HIV infection.

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Souza, Rafael Leme Cardoso. "Avaliação tecnológica do teste molecular (NAT) para HIV, HCV e HBV na triagem de sangue no Brasil". Universidade de São Paulo, 2018. http://www.teses.usp.br/teses/disponiveis/99/99131/tde-09102018-090250/.

Texto completo da fonte

Resumo:

Após anos de debates, o teste de detecção de ácidos nucleicos (NAT) para HIV e HCV na triagem de sangue foi implementado de forma obrigatória no Brasil em 2013, e HBV, em 2016. Um dos motivos citados sobre o atraso em sua implementação foi o custo elevado que seria adicionado à sorologia e, até o momento, uma ampla avaliação econômica em saúde (AES) a respeito de sua eficiência no país não está disponível. Diversos artigos já demonstraram que a razão incremental de custo-utilidade (ICUR) do NAT em relação à sorologia varia de 0,21 a 8,84 milhões de dólares americanos (US$) para cada QALY ganho. Esta grande variação dá-se, principalmente, por diferenças entre a idade média dos receptores de sangue (RS), incidência/prevalência dos vírus entre os doadores de sangue (DS), custo dos testes e tratamentos médicos, cobertura da vacina contra o HBV e sensibilidade do teste utilizado. Assim, faz-se necessária uma avaliação abrangente desta tecnologia e sua efetividade para o cenário brasileiro. Objetivos: Realizar uma revisão sistemática (RevS) de estudos econômicos completos sobre o uso do NAT para HIV, HCV e/ou HBV no mundo; realizar a AES sobre o NAT sob a perspectiva pública brasileira; caracterizar as doações de sangue em janela imunológica no país. Métodos: Metodologia Cochrane de RevS das bases de dados Medline, Embase, LILACS, CRD, BVS ECO, Google Scholar e IDEAS; questionário aplicado aos bancos de sangue e modelo econômico on-line da International Society of Blood Transfusion (ISBT) para cálculo da ICUR do \"NAT em mini-pool de seis amostras individuais\" (MP6) versus \"testes sorológicos\" (SR) no Brasil. Resultados: Quatorze estudos de dezesseis diferentes países foram avaliados. O NAT apresentou a maior relevância nos países de baixa renda, onde há as maiores prevalências e incidências virais, menores taxas de doadores de repetição (DR) e RS mais jovens. A maioria dos estudos concluiu que o NAT, independente do vírus analisado, não é custo-efetivo. As principais diferenças entre as características dos estudos foram relacionadas aos custos médicos e idade dos RS. O maior desvio dos padrões de uma RevS foram: não incluir o racional para definição dos desfechos e o modelo utilizado e não ter claro o conflito de interesse dos autores; para esta AES, o MP6 versus SR apresentou um ICUR de US$ 231.630,00/QALY, ou seja, 26,2 vezes o PIB per capita nacional) e um ICER de US$ 330.790,00/Ano de vida ganho (AVG). A análise de sensibilidade univariada do modelo demonstrou que somente a taxa de desconto, idade do RS, custo do NAT e epidemiologia dos vírus alteraram de forma significativa o ICUR obtido, variando desde US$ 76.957,00/QALY a US$ 933.311,00/QALY; a maioria dos casos de janela imunológica no Brasil são jovens, média de 29 anos, do sexo masculino, com pelo menos o ensino médio completo e mesmo com a obrigatoriedade do Anti-HBc no Brasil, o NAT-HBV é o que apresentou o maior rendimento. Conclusões: Os jovens, principalmente, ainda buscam os bancos de sangue como locais de testagem após comportamento de risco e é de extrema importância a revisão do custo real e completo do teste NAT no Brasil para ampla abordagem da tecnologia nacional incorporada e, se necessário, revisar a forma e modelo de reembolso da mesma e permitir a defesa do bem-estar da população e do bem público.
After years of discussion, nucleic acid (NAT) testing in the blood screening for HIV and HCV was implemented in Brazil in 2013 and HBV in 2016. One of the reasons cited for the delay in its implementation was the high cost that would be added to serology screening and a comprehensive economic assessment of its efficiency in the country is not yet available. Several articles have already shown that the incremental cost-utility ratio (ICUR) of NAT versus serology ranges from 0.21 to 8.84 million American dollars (US$) for each QALY gained. This large variation is mainly due to differences between the mean age of the blood recipient, viruses\' incidence / prevalence among donor population, cost of medical tests and treatments, HBV vaccine coverage, and sensitivity of the test used. Thus, a comprehensive evaluation of this technology and its effectiveness under the perspective of the Brazilian public health system (SUS) is needed. Objectives: Development of a systematic review (RevS) of complete economic studies about the use of NAT for HIV, HCV and / or HBV in the world. Conduct an economic evaluation of NAT under SUS perspective; characterize Brazilian blood donations in the serology \"window period\". Methods: Cochrane RevS Methodology of the Medline, Embase, LILACS, CRD, CRD ECO, Google Scholar and IDEAS databases; Questionnaire applied to blood banks and online economic model from the International Society of Blood Transfusion (ISBT) to calculate the ICUR for \"NAT in mini-pool of six individual samples\" (MP6) versus \"Serology Tests\" (SR) in Brazil. Results: Fourteen studies from sixteen different countries were assessed. NAT was most relevant in low-income countries, where there are the highest prevalences and viral incidences, lower rates of repeat donors and younger recipients of blood (RS). Most of the studies concluded that NAT, regardless of the virus evaluated, is not cost-effective. Differences in the characteristics of the studies were related to the costs and age of RS. The major deviations from RevS standards were: not including the rationale for selecting the outcomes and the model used and not being clear about the authors\' conflict of interest; MP6 vs SR showed an ICUR of US$ 231.630,00/QALY, 26,2 times Brazilian GND per capita) and an ICER of US$ 330.790,00/Life year gained (AVG). The univariate sensitivity analysis of the model demonstrated that only changes on discount rate, NAT cost, RS age and viruses\' epidemiology significantly altered the ICUR in a range between US$ 76.957,00/QALY and US$ 933.311,00/QALY; Most RS window period cases in Brazil are young, average of 29 years old, male, with at least high school education completed and even with the requirement of Anti-HBc in Brazil, NAT-HBV is the one that presented the highest yield. Conclusions: Young people, mainly, still seek blood banks as testing sites, especially after a risk behavior. It is extremely important to reveal the real and complete cost of the Brazilian NAT to fully evaluate its efficiency and, if needed, reassess its current reimbursement model, allowing the wellbeing defense of the population and public interest.

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Del-Rios, Nativa Helena Alves. "Estudo epidemiológico e molecular da infecção pelo vírus da Hepatite C em indivíduos infectados pelo vírus da Imunodeficiência Humana em Goiânia-Goiás". Universidade Federal de Goiás, 2011. http://repositorio.bc.ufg.br/tede/handle/tede/7241.

Texto completo da fonte

Resumo:

Submitted by Erika Demachki (erikademachki@gmail.com) on 2017-04-27T18:05:38Z No. of bitstreams: 2 Dissertação - Nativa Helena Alves Del-Rios - 2011.pdf: 2685862 bytes, checksum: a88d60dfeef4b6b920f7a23cc00881a3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Rejected by Erika Demachki (erikademachki@gmail.com), reason: on 2017-04-27T18:05:52Z (GMT)
Submitted by Erika Demachki (erikademachki@gmail.com) on 2017-04-27T18:06:12Z No. of bitstreams: 2 Dissertação - Nativa Helena Alves Del-Rios - 2011.pdf: 2685862 bytes, checksum: a88d60dfeef4b6b920f7a23cc00881a3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2017-05-03T11:47:33Z (GMT) No. of bitstreams: 2 Dissertação - Nativa Helena Alves Del-Rios - 2011.pdf: 2685862 bytes, checksum: a88d60dfeef4b6b920f7a23cc00881a3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Made available in DSpace on 2017-05-03T11:47:33Z (GMT). No. of bitstreams: 2 Dissertação - Nativa Helena Alves Del-Rios - 2011.pdf: 2685862 bytes, checksum: a88d60dfeef4b6b920f7a23cc00881a3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2011-03-30
Fundação de Amparo à Pesquisa do Estado de Goiás - FAPEG
The hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are characterized by causing chronic infections in the host. The advent of potent antiretroviral therapy has resulted in a significant reduction in the incidence of opportunist infections, and thus greater life expectancy for HIV positive patients. However, the liver disease appears as a major cause of morbidity and mortality among these patients, especially those related to hepatitis C virus. Co-infection with HCV/HIV induces a worse prognosis for both infections, which may lead to the development of AIDS, a faster rapid evolution to chronic active hepatitis and / or liver cirrhosis and death. This study aimed to investigate the epidemiology and molecular profile HCV infection in HIV-infected individuals with no prior antiretroviral therapy, seen in the referral hospital for the treatment of infectious diseases (Hospital for Tropical Diseases - Anuar Auad / HDT) in Goiania, Goiás. A total of 505 treatment naïve individuals and were referred to the HDT, from April 2009 to April 2010 were interviewed and underwent blood collection. All sera were tested for antibodies to HCV (anti-HCV) and for HCV RNA by polymerase chain reaction (PCR). Genotyping was performed by reverse hybridization by the Line Probe Assay (LiPA) method. The prevalence of anti-HCV was 4.6% (95% CI: 3.0 to 6.8). The viral RNA was detected in 65.2% (15/23) of anti-HCV positive samples. The genotypes identified were 1 (subtypes 1a and 1b) and 3 (subtype 3a). The age > 40 years, living in other states or Goiania city, surgery, injecting and non-injecting drug and anti-HBc positive (antibody to core antigen of hepatitis B virus) were associated with HCV infection after logistic regression. The data presented shows the vulnerability of the HIV sropositive population to acquisition of infectious diseases such as HCV infection. Thus, the information obtained will be essential for planning public health interventions, preventing and control of hepatitis C in this population.
Os vírus da hepatite C (HCV) e da imunodeficiência humana (HIV) causam infecções crônicas no hospedeiro. O advento da terapia antiretroviral potente trouxe uma redução da incidência de infecções oportunistas, e consequentemente, uma maior expectativa de vida aos pacientes HIV soropositivos. No entanto, as hepatopatias surgem como uma das principais causas de morbimortalidade entre esses pacientes, principalmente aquelas relacionadas ao vírus C. A coinfecção HCV/HIV induz a um pior prognóstico de ambas as infecções, podendo levar ao desenvolvimento da Aids, evolução mais rápida para hepatite crônica ativa e/ou cirrose hepática e morte. Este estudo teve como objetivo investigar o perfil epidemiológico e molecular da infecção pelo HCV em indivíduos infectados pelo HIV, sem tratamento antiretroviral prévio, atendidos no Hospital de referência para o tratamento de doenças infecciosas (Hospital de Doenças Tropicais - Anuar Auad / HDT) em Goiânia, Goiás. Um total de 505 indivíduos, virgens de tratamento, encaminhados ao HDT, no período de abril/2009 a abril/2010, foram entrevistados e submetidos à coleta de sangue. As amostras (soros) foram testadas para a detecção de anticorpos para o HCV (ELISA/LIA) e submetidas à identificação do RNA-HCV pela reação em cadeia da polimerase (PCR). A genotipagem foi realizada por hibridização reversa, pelo método Line Probe Assay (LiPA). A prevalência para anti-HCV foi de 4,6% (IC 95%: 3,0-6,8). O RNA viral foi detectado em 15 amostras, sendo todas elas anti-HCV positivas. Foram identificados os genótipos 1 e 3, com predomínio do subtipo 1a, seguido dos subtipos 1b e 3a. As variáveis idade superior a 40 anos, ser procedente de Goiânia ou outros estados, cirurgia, uso de drogas injetáveis e não-injetáveis, história de prisão e positividade ao anti-HBc foram associados à infecção pelo vírus da hepatite C, após regressão logística. Os dados apresentados revelam a vulnerabilidade da população HIV soropositiva à aquisição de doenças infecciosas como a infecção pelo HCV. Assim, as informações obtidas serão essenciais para o planejamento de ações de saúde pública para a prevenção e controle da hepatite C nessa população.

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Gröner, Jan Benedikt. "Mitochondriale Dysfunktion bei chronischer Hepatitis B, chronischer Hepatitis C und bei HIV-Postexpositionsprophylaxe". Diss., lmu, 2011. http://nbn-resolving.de/urn:nbn:de:bvb:19-135665.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

Barbosa, Alexandre Naime [UNESP]. "Avaliação das citocinas (ELISA e RT-PCR) e da fibrose hepática na coinfecção pelo HIV e vírus da hepatite C". Universidade Estadual Paulista (UNESP), 2010. http://hdl.handle.net/11449/101466.

Texto completo da fonte

Resumo:

Made available in DSpace on 2014-06-11T19:31:28Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-06-18Bitstream added on 2014-06-13T18:42:08Z : No. of bitstreams: 1 barbosa_an_dr_botfm.pdf: 1241955 bytes, checksum: 4ebec113ac46c15142666ca4f710746d (MD5)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Universidade Estadual Paulista (UNESP)
A aids e a hepatite C crônica são infecções caracterizadas por importante processo inflamatório contínuo, regulado por uma complexa interação entre citocinas. A persistência da atividade inflamatória crônica está intimamente relacionada com a progressão da patogênese da aids, bem como na indução de fibrose na hepatite C. Com o objetivo de avaliar o padrão de citocinas na infecção pelo HIV e na hepatite C crônica, as citocinas IL-2, IL-4, IL-10, TNF-α, INF-γ, TGF-β foram dosadas por Elisa e RT-PCR em cinco grupos: pacientes coinfectados pelo HIV/VHC (n=22), monoinfectados pelo HIV com supressão virológica pelo tratamento, e sem supressão virológica (n=17), monoinfectados pelo VHC (n=22) e um grupo controle composto por indivíduos doadores de sangue (n=10). IL-4 e IL-10 estiveram aumentadas consistentemente nos quatro grupos de estudo, determinando predomínio do perfil Th-2. INF-γ, TNF-α e TGF-β estiveram aumentados apenas nos grupos com infecção pelo VHC, com ou sem coinfecção pelo HIV. No grupo de monoinfectados pelo HIV com supressão virológica, a IL-2 dosada por RT-RCR esteve aumentada, porém os níveis séricos dosados por Elisa estavam normais. A alta produção de citocinas pró-inflamatórias INF-γ, TNF-α e TGF-β nos dois grupos de pacientes com infecção pelo VHC refletem o processo progressivo de acúmulo de inflamação e fibrose hepática. Já o predomínio de IL-4 e IL-10 em todos os grupos, citocinas ligadas ao perfil Th-2, demonstram a incapacidade de produção de uma resposta citotóxica Th-1, perpetuando a infecção e a inflamação crônica, mesmo naqueles indivíduos com supressão virológica pelo tratamento. Além de drogas antivirais, novos tratamentos imunomoduladores têm sido propostos para a erradicação viral, ou a interrupção das lesões causadas pelo estado inflamatório crônico...
Both AIDS and chronic hepatitis C (HCV) are characterized by continuous inflammatory process, regulated by a complex interaction between cytokines. The persistence of chronic inflammatory activity is closely related to the progression of the pathogenesis of AIDS, as well as the induction of fibrosis in HCV. In order to analyze the role of cytokines in HIV/HCV coinfection and the fibrosis progression, IL-2, IL-4, IL-10, TNF- α, INF-γ, TGF-β were measured by ELISA and RT -PCR in five groups: HIV/HCV coinfected patients (n = 22), HCV monoinfected patients (n = 22), HIV monoinfected patients with and without virological suppression (n = 17) and a control group composed by blood donors (n = 10). Hepatic biopsy and METAVIR classification were performed in all HCV patients (n=44). The baseline characteristics (sex, age and race) of all groups were similar. No correlations were found between cytokines and hepatic fibrosis. IL-4 and IL-10 were consistently increased in the four study groups, findings associated to a Th-2 profile. INF- γ, TNF-α and TGF-β were increased only in groups with HCV infection. In the group of HIV monoinfected patients with virological suppression, IL-2 measured by RT-RCR was increased, but serum levels measured by ELISA were normal. The high production of proinflammatory cytokines INF-γ, TNF-α and TGF-β in two groups of patients with HCV infection reflect the gradual process of inflammation and liver fibrosis. The predominance of IL-4 and IL-10 in all study groups demonstrates an inability to promote a cytotoxic Th-1 response. Even in HIV monoinfected patients with virological suppression with increased IL-2 expression, Th-2 cytokines were the predominant, perpetuating the chronic inflammation. In addition to antiviral drugs, new immunomodulatory treatments have been proposed... (Complete abstract click electronic access below)

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Barbosa, Alexandre Naime. "Avaliação das citocinas (ELISA e RT-PCR) e da fibrose hepática na coinfecção pelo HIV e vírus da hepatite C /". Botucatu : [s.n.], 2010. http://hdl.handle.net/11449/101466.

Texto completo da fonte

Resumo:

Orientador: Domingues Alves Meira
Banca: Alexandrina Sartori
Banca: Ricardo Sobhie Diaz
Banca: Fernando Lopes Gonçalves Júnior
Resumo: A aids e a hepatite C crônica são infecções caracterizadas por importante processo inflamatório contínuo, regulado por uma complexa interação entre citocinas. A persistência da atividade inflamatória crônica está intimamente relacionada com a progressão da patogênese da aids, bem como na indução de fibrose na hepatite C. Com o objetivo de avaliar o padrão de citocinas na infecção pelo HIV e na hepatite C crônica, as citocinas IL-2, IL-4, IL-10, TNF-α, INF-γ, TGF-β foram dosadas por Elisa e RT-PCR em cinco grupos: pacientes coinfectados pelo HIV/VHC (n=22), monoinfectados pelo HIV com supressão virológica pelo tratamento, e sem supressão virológica (n=17), monoinfectados pelo VHC (n=22) e um grupo controle composto por indivíduos doadores de sangue (n=10). IL-4 e IL-10 estiveram aumentadas consistentemente nos quatro grupos de estudo, determinando predomínio do perfil Th-2. INF-γ, TNF-α e TGF-β estiveram aumentados apenas nos grupos com infecção pelo VHC, com ou sem coinfecção pelo HIV. No grupo de monoinfectados pelo HIV com supressão virológica, a IL-2 dosada por RT-RCR esteve aumentada, porém os níveis séricos dosados por Elisa estavam normais. A alta produção de citocinas pró-inflamatórias INF-γ, TNF-α e TGF-β nos dois grupos de pacientes com infecção pelo VHC refletem o processo progressivo de acúmulo de inflamação e fibrose hepática. Já o predomínio de IL-4 e IL-10 em todos os grupos, citocinas ligadas ao perfil Th-2, demonstram a incapacidade de produção de uma resposta citotóxica Th-1, perpetuando a infecção e a inflamação crônica, mesmo naqueles indivíduos com supressão virológica pelo tratamento. Além de drogas antivirais, novos tratamentos imunomoduladores têm sido propostos para a erradicação viral, ou a interrupção das lesões causadas pelo estado inflamatório crônico... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: Both AIDS and chronic hepatitis C (HCV) are characterized by continuous inflammatory process, regulated by a complex interaction between cytokines. The persistence of chronic inflammatory activity is closely related to the progression of the pathogenesis of AIDS, as well as the induction of fibrosis in HCV. In order to analyze the role of cytokines in HIV/HCV coinfection and the fibrosis progression, IL-2, IL-4, IL-10, TNF- α, INF-γ, TGF-β were measured by ELISA and RT -PCR in five groups: HIV/HCV coinfected patients (n = 22), HCV monoinfected patients (n = 22), HIV monoinfected patients with and without virological suppression (n = 17) and a control group composed by blood donors (n = 10). Hepatic biopsy and METAVIR classification were performed in all HCV patients (n=44). The baseline characteristics (sex, age and race) of all groups were similar. No correlations were found between cytokines and hepatic fibrosis. IL-4 and IL-10 were consistently increased in the four study groups, findings associated to a Th-2 profile. INF- γ, TNF-α and TGF-β were increased only in groups with HCV infection. In the group of HIV monoinfected patients with virological suppression, IL-2 measured by RT-RCR was increased, but serum levels measured by ELISA were normal. The high production of proinflammatory cytokines INF-γ, TNF-α and TGF-β in two groups of patients with HCV infection reflect the gradual process of inflammation and liver fibrosis. The predominance of IL-4 and IL-10 in all study groups demonstrates an inability to promote a cytotoxic Th-1 response. Even in HIV monoinfected patients with virological suppression with increased IL-2 expression, Th-2 cytokines were the predominant, perpetuating the chronic inflammation. In addition to antiviral drugs, new immunomodulatory treatments have been proposed... (Complete abstract click electronic access below)
Doutor

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Ferreira, Ariana Carolina. "Pesquisa de marcadores sorológicos e moleculares da infecção pelo Vírus da Hepatite E (HEV) em indivíduos portadores do Vírus da Imunodeficiência Humana (HIV)". Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/5/5168/tde-30062016-115114/.

Texto completo da fonte

Resumo:

A infecção pelo HEV é reconhecida como um considerável problema de saúde pública em diversas regiões do mundo. Embora caracterizada como uma infecção benigna com um curso evolutivo autolimitado, recentes estudos têm mostrado sua evolução para cronicidade em indivíduos imunocomprometidos. Além disso, tem sido verificado que nesses indivíduos a infecção crônica pelo HEV pode evoluir para fibrose hepática progressiva, culminando com o desenvolvimento de cirrose. Não existem dados acerca da prevalência da infecção pelo HEV em pacientes infectados pelo HIV no Brasil, onde a circulação deste vírus tem sido demonstrada em diversos grupos de indivíduos imunocompetentes e, até mesmo, em alguns animais provenientes de diferentes regiões do país. Com base nisso, este trabalho teve como objetivo estimar a prevalência de marcadores sorológicos e moleculares da infecção pelo HEV, bem como a padronização de uma PCR em tempo real para a detecção e quantificação da carga viral do HEV na população de soropositivos da cidade de São Paulo. Foram incluídos neste estudo soro e plasma de pacientes infectados pelo HIV (n=354), que foram divididos em grupos de acordo com a presença ou ausência de coinfecção pelos vírus das hepatites B (HBV) e C (HCV). Essas amostras foram coletadas entre 2007 e 2013. Anticorpos anti-HEV IgM e IgG foram pesquisados pela técnica de ELISA (RecomWell HEV IgM/ IgG - MIKROGEN®), e, em alguns casos, confirmados por Immunoblotting (RecomLine HEV IgM/ IgG - MIKROGEN®). Todas as amostras foram submetidas à pesquisa de HEV RNA através da PCR em tempo real padronizada. Cerca de 72% dos indivíduos avaliados pertenciam ao sexo masculino. A média de idade entre a população analisada foi de 48,4 anos. Os anticorpos anti-HEV IgM e IgG foram encontrados em 1,4% e 10,7% dos indivíduos dessa população, respectivamente. Apenas dois pacientes apresentaram positividade simultânea para anti-HEV IgM e IgG. Não houve diferença estatisticamente relevante quanto à presença de marcadores sorológicos nos grupos de estudo. Além disso, foi detectado o HEV RNA em 10,7% das amostras analisadas, entre as quais, seis apresentaram simultaneamente algum marcador sorológico (5 anti-HEV IgG e 1 IgM). A presença deste marcador foi predominante no grupo de pacientes com coinfecção pelo HCV. Através deste trabalho pôde-se constatar, portanto, que o HEV é circulante entre a população de infectados pelo HIV em São Paulo, e que o seguimento desses pacientes se faz necessário dado a possibilidade de progressão para infecção crônica e cirrose
HEV infection is recognized as a significant public health problem in different world regions. Although initially characterized as a benign infection with selflimited course, recent studies have showing its evolution to chronicity in immunocompromised individuals. Furthermore, in these individuals the chronic infection can develop progressive liver fibrosis leading to cirrhosis. There are no data regarding prevalence of HEV infections in HIV- infected patients in Brazil, where the circulation of this virus has been demonstrated in different individuals groups and in some animals from different regions of the country. Based on this, this study aimed to assess the prevalence of serological and molecular makers of HEV infection and the standardization of real-time PCR for the detection and quantification of HEV viral load in HIV-infected individuals in São Paulo. Serum and plasma samples of HIV-infected patients (n=354), collected between 2007 and 2013, were included and organized in groups of co-infection (HIV/ HBV, HIV/HCV and HIV/ HBV/ HCV) and HIV mono-infection. Antibodies anti-HEV IgM and IgG were detected by ELISA (RecomWell HEV IgM/ IgG - MIKROGEN®), and in some cases confirmed by immunoblotting (RecomLine HEV IgM/ IgG - MIKROGEN®). All samples were submitted to research HEV RNA by real-time PCR. About 72% of the patients were male. The mean age of this population was 48.4 years. The anti-HEV IgM and IgG antibodies were found in 1.4% and 10.7%, respectively. Only two patients presented simultaneous anti-HEV IgM and anti- HEV IgG. There was no statistically significant difference in the presence of serological makers among the HIV infection groups. In addition, HEV RNA was detected in 10.7% of samples and six of these samples presented simultaneously a serological maker (5 anti-HEV IgG and 1 IgM). The presence of this maker was more frequent in the co-infection HIV/ HCV group. Through this work, we observed that HEV is circulating among the HIV-infected population in São Paulo, and the monitoring these patients is necessary because of the possibility progression to chronic infection and cirrhosis

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Alencar, Wong Kuen. "Análise de sobrevida de pacientes coinfectados HIV/HCV de um centro de referência em DST/AIDS no município de São Paulo". Universidade de São Paulo, 2011. http://www.teses.usp.br/teses/disponiveis/6/6132/tde-30092011-133057/.

Texto completo da fonte

Resumo:

Introdução: A estimativa de sobrevida de pacientes com HIV/aids aumentou após a terapia antirretroviral de alta potência: no entanto, a mortalidade por doenças hepáticas também cresceu. Objetivos: Estimar a probabilidade acumulada de sobrevida após o diagnóstico de aids entre pacientes coinfectados HIV/HCV e realizar análise exploratória para investigar fatores relacionados à sobrevida desses pacientes. Metodologia: Estudo de coorte não concorrente, utilizando sistemas de Informações: o de Agravos de Notificação, o de informação laboratorial e o de informação da vigilância epidemiológica do Centro de Referência e Treinamento DST/AIDS-SP, de pacientes com aids maiores de 13 anos, acompanhados no ambulatório geral. As variáveis estudadas foram: hepatite C, hepatite B, categoria de exposição, contagem de células T CD4+, faixa etária, escolaridade, cor, sexo e períodos de diagnóstico de aids: 1986 a 1993, 1994 a 1996, 1997 a 2002 e 2003 a 2010. Foi utilizado o estimador de Kaplan-Meier, o modelo de Cox e as estimativas das hazard ratio (HR) com os respectivos intervalos de confiança (IC 95 por cento ). Resultados: De um total de 2.864 pessoas incluídas, com idade mediana de 35 anos, 219 foram a óbito (7,5 por cento ). De 358 (12,5 por cento ) coinfectados, 159 (45,1 por cento ) eram usuários de drogas injetáveis (UDI) e de 2.506 não coinfectados, 96 (3,9 por cento ) eram UDI. A probabilidade acumulada de sobrevida entre coinfectados, a partir do diagnóstico de aids, foi 100 por cento aos 60 meses no período de 1986 a 1993; 27,8 por cento aos 168 meses no período de 1994 a 1996; 76,3 por cento aos 168 meses no período de 1997 a 2002 e 92,8 por cento aos 96 meses no período de 2003 a 2010. As curvas de sobrevida foram diferentes entre coinfectados e não coinfectados no período de 1994 a 1996 (log rank = 19,8; p < 0,001) e no período de 1997 a 2002 (log rank = 38,8; p < 0,001). No modelo de Cox multivariado, mostraram-se preditores de óbito, independentemente das outras variáveis: ter hepatite C (HR = 2,9; IC 2,1-3,9), ter hepatite B (HR = 2,5; IC 1,7-3,6), ter até 3 anos de estudo (HR = 2,3; IC 1,5-3,6), ter 50 anos ou mais de idade (HR = 2,1; IC 1,3-3,2). Ter diagnóstico de aids no período entre 1997 a 2002 mostrou-se fator de proteção ao óbito (HR = 0,4; IC 0,3-0,5). Conclusões: Coinfectados HIV/HCV apresentaram menor sobrevida quando comparado com não coinfectados nos períodos de diagnóstico de aids 1994 a 1996 e 1997 a 2002. A partir do período 1994 a 1996, observou-se aumento significativo na probabilidade acumulada de sobrevida entre coinfectados, sendo que no período 2003 a 2010, essa probabilidade foi semelhante entre coinfectados e não coinfectados, refletindo possível impacto do tratamento da hepatite C
Introduction: The estimated survival of patients with HIV/AIDS has increased after highly active antiretroviral therapy; mortality due to liver diseases, however, has also increased. Objectives: To estimate the accumulated probability of survival after AIDS diagnosis among HIV/HCV co-infected individuals and to perform an exploratory analysis to investigate factors related to the survival of these patients. Method: Non-concurrent cohort study, using data from the National Disease Reporting Information System, the laboratory and epidemiological surveillance information systems of the SP-STD Reference and Training Center-CRT, of patients over 13 years of age, followed at the general outpatient clinic. The following variables were studied: hepatitis C, hepatitis B, exposure category, T CD4+ cell count, age group, schooling, color, sex, and AIDS diagnostic periods: 1986 to 1993, 1994 to 1996, 1997 to 2002 and 2003 to 2010. Survival analysis was performed using the Kaplan-Meier estimator and the Cox model, with estimates of the hazard ratio (HR) and respective confidence intervals (95 per cent CI). Results: Of a total of 2,864 individuals included, with a median age of 35 years, 219 died (7.5 per cent ). Of the 358 (12.5 per cent ) HIV/HCV co-infected individuals, 159 (45.1 per cent ) were injecting drug users (IDU), and of the non-co-infected 2,506, 96 (3.9 per cent ) were IDU. The accumulated probability of survival among HIV/HCV co-infected individuals at 60, 168, 168 and 96 months as of AIDS diagnosis, was 100 per cent in the 1986 -1993 period; 27,8 per cent in the 1994-1996 period; 76,3 per cent in the 1997-2002 period; and 92,8 per cent in the 2003-2010 period. The survival curves were different between co-infected and non-co-infected individuals in the 1994-1996 (log rank = 19,8; p < 0,001) and in the 1997-2002 (log rank = 38,8; p < 0,001). In the multivariate model, regardless of other variables, the following were predictors of death: having hepatitis C (HR = 2.9; CI 2.1-3.9); having hepatitis B (HR = 2.5; CI 1.7-3.6); being 50 years old or over (HR = 2.1; CI 1.3-3.2) and having up to 3 years of schooling (HR = 2.3; CI 1.5-3.6). AIDS diagnosis between 1997 and 2010 was shown to be a protective factor for death (HR = 0.4; CI 0.3-0.5). Conclusions: HIV/HCV co-infected individuals had shorter survival, when compared to non-co-infected individuals in the 1994-1996 and in the 1997-2002 AIDS diagnostic periods. As of the 1994-1996 period, a significant increase in the accumulated probability of survival among HIV/HCV co-infected individuals was observed. In the 2003-2010 period, the probability was similar between co-infected and non-coinfected individuals, showing the possible impact of hepatitis treatment

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Brandão, Natália Alberto Alves. "Prevalência e fatores associados às infecções pelos vírus das hepatites B e C em pacientes HIV positivos, atendidos na rede pública de Goiânia - Goiás". Universidade Federal de Goiás, 2013. http://repositorio.bc.ufg.br/tede/handle/tede/3534.

Texto completo da fonte

Resumo:

Submitted by Marlene Santos (marlene.bc.ufg@gmail.com) on 2014-11-04T19:15:44Z No. of bitstreams: 2 Dissertação - Natália Alberto Alves Brandão.pdf: 2752228 bytes, checksum: f1f4834b88d60df4f5620fe3e16ff30d (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)
Approved for entry into archive by Jaqueline Silva (jtas29@gmail.com) on 2014-11-05T09:19:23Z (GMT) No. of bitstreams: 2 Dissertação - Natália Alberto Alves Brandão.pdf: 2752228 bytes, checksum: f1f4834b88d60df4f5620fe3e16ff30d (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)
Made available in DSpace on 2014-11-05T09:19:23Z (GMT). No. of bitstreams: 2 Dissertação - Natália Alberto Alves Brandão.pdf: 2752228 bytes, checksum: f1f4834b88d60df4f5620fe3e16ff30d (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Previous issue date: 2013-05-06
Hepatitis B and C viruses are responsible for the most common chronic viral infections worldwide. The prevalence of these viruses is higher among HIV-infected individuals, due to common route of transmission. Coinfections HBV / HIV and HCV / HIV seems to be associated with a worst liver disease prognosis. Studies evaluating these coinfections in the mid-western Brazil are scarce. Objectives: To estimate the prevalence and the risk factors associated with HBV and HCV coinfections in HIV-positive patients in Goiânia – Goiás. Methods: A cross-sectional study was conducted including 495 adults, recruited from the Centro de Referência em Diagnóstico e Terapêutica de Goiânia in 2011. After signing the informed consent, participants were interviewed and material was collected for research markers for HBV (anti-HBc, HBsAg, anti-HBs and HBV DNA) and HCV (anti-HCV and HCV RNA). Prevalence of HBV and HCV infection was estimated. Univariate and multivariate analysis to evaluate factors associated with positivity for both viruses were performed. Odds and adjusted odds ratios were calculated with 95% confidence intervals (CI95%) and a significance level of p<0.05. Results: Participants mean age was 40.2 years (standard deviation =10. 4) with a male predominance (73.9%). Injecting drugs usage was reported by 3.6% of participants. The prevalence of markers for hepatitis B exposure was 33.5% (CI95% 29.4-37.9). Nineteen patients (3.8%, CI95% 2.4-6.0) were diagnosed as hepatitis B carriers. Prevalence of anti-HCV was 9.7% (CI95% 7.3-12.7). The distribution of HCV genotypes was: 1a (72.7%), 3 (13.6%) and 1b (9.1%). Coinfection by the three viruses was 4.4% (CI95% 2.9-6.8). Male, age ≥ 40 years, previous history of sexually transmitted disease (STD) and homo or bisexuality were associated with exposure to HBV. History of injecting drugs and STD were associated with HCV seropositivity. Over half of the coinfected patients were not aware of being HBV or HCV positive. Conclusion: Seromarkers for previous HBV and/or HCV infections are common among individual HIV positives in Goiânia. A significant proportion of them are unaware of their serological status. These findings suggest the need for better screening and guidance improvements for this population
Os vírus das hepatites B (HBV) e C (HCV) são responsáveis pelas infecções crônicas virais mais comuns em todo o mundo. A prevalência dessas infecções é maior entre indivíduos infectados pelo HIV, devido às vias comuns de transmissão desses vírus. As coinfecções HBV/HIV e HCV/HIV parecem estar associadas a um pior prognóstico da doença hepática. Estudos avaliando essas coinfecções, na região centro-oeste do Brasil, são escassos. Objetivos: Estimar a prevalência e analisar fatores sócio-demográficos e comportamentais associados às infecções pelo HBV e HCV em pacientes HIV positivos. Métodos: Estudo transversal, com inclusão de 495 pacientes adultos, recrutados no Centro de Referência em Diagnóstico e Terapêutica de Goiânia, em 2011. Após assinatura do termo de consentimento livre e esclarecido, os participantes foram entrevistados e coletouse material para pesquisa de marcadores para o HBV (anti-HBc, HBsAg, anti-HBs e HBV DNA) e HCV (anti-HCV e HCV RNA). Estimou-se a prevalência das infecções pelo HBV e HCV. Foi realizada análise uni e multivariada para avaliar fatores associados com a positividade para os dois vírus. Foram calculados os Odds Ratios brutos e ajustados com respectivos intervalos de 95% de confiança (IC95%) e nível de significância de p<0,05. Resultados: A média de idade dos participantes foi de 40,2 anos (desvio padrão=10,4), com predomínio de homens (73,9%). O relato de uso de drogas injetáveis foi feito por 3,6% dos participantes. A prevalência de exposição ao vírus da hepatite B foi de 33,5% (IC95% 29,4-37,9). Dezenove pacientes (3,8%, IC95% 2,4-6,0) foram diagnosticados como portadores do vírus da hepatite B. A prevalência de anti-HCV foi 9,7% (IC95% 7,312,7). A distribuição dos genótipos do HCV nessa população foi: 1a (72,7%), 3 (13,6%) e 1b (9,1%). A coinfecção pelos três vírus foi de 4,4% (IC95% 2,9-6,8). Sexo masculino, idade ≥ 40 anos, relato de doença sexualmente transmissível (DST) e homo ou bissexualismo mostraram-se associados à presença de marcadores de exposição ao HBV. Antecedentes de drogas injetáveis e DST mostraram associação com soropositividade para HCV. Cerca da metade dos pacientes coinfectados não sabia ser HBV ou HCV positivos. Conclusões: Marcadores de exposição prévia ao HBV e ao HCV são frequentes entre os pacientes HIV positivos, em Goiânia. Uma parcela significativa dessa população desconhece seu status sorológico, sugerindo a necessidade de medidas de triagem e de orientação mais efetivas.

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Burke, Stephanie. "Generalized Impairment of CD8+ T-cells in HCV Mono- and HIV-HCV Co-infection". Thesis, Université d'Ottawa / University of Ottawa, 2015. http://hdl.handle.net/10393/32770.

Texto completo da fonte

Resumo:

Chronic hepatitis C virus (HCV) infection has global effects on the immune system. CD8+ T-cells, responsible for viral clearance and control, are dysfunctional for as yet unknown reasons. It is hypothesized that IL-7 signaling pathway deficiencies contribute to this impairment. Blood-derived CD8+ T-cells in chronic HCV mono- and HIV-HCV co-infection had lower IL-7-induced activation of STAT5 and production of Bcl-2, and lower proliferation in co-infection, compared to controls. Lower Bcl-2 production was also associated with increased fibrosis. These changes were independent of the IL-7 receptor α expression and suppressor of cytokine signaling 1 or 3 expression. Intrahepatic CD8+ T-cells in HCV-infection did not activate STAT5 above basal levels with cytokine stimulation and had lower Bcl-2 expression than blood-derived cells. In conclusion, bulk CD8+ T-cells were impaired in response to IL-7 and the IL-7 signaling pathway may be one mechanism by which CD8+ T-cells are impaired in chronic HCV infection.

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Herreru-MartiÌnez, Esteban. "Hepatitis C and HIV co-infection in patients with haemophilia". Thesis, University College London (University of London), 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.404936.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Gao, Zhanhai School of Mathematics UNSW. "Modelling Human Immunodeficiency Virus and Hepatitis C Virus Epidemics in Australia". Awarded by:University of New South Wales. School of Mathematics, 2001. http://handle.unsw.edu.au/1959.4/18187.

Texto completo da fonte

Resumo:

This thesis is concerned with the mathematical modelling for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) epidemics in Australia. There are two parts to this thesis. Part I is aimed at modelling the transmission of HIV and HCV via needle sharing among injecting drug users (IDUs). The dynamical model of an epidemic through needle sharing among IDUs is derived. This model reveals the correlation between needle sharing and the epidemic prevalence among IDUs. The simulations of HIV and HCV prevalence and incidence among IDUs in Australia are made with this model. The comparison of simulated results with literature estimates shows that the modelled results are consistent with the literature estimates. The effects of needle sharing and cleaning on HIV and HCV prevalence and incidence among IDUs in Australia are evaluated. Part II is devoted to modelling the spread of HIV in the general community in Australia. A mathematical model is formulated to assess the epidemiological consequences of injecting drug use and sexual transmission in Australia. The effects of highly active antiretroviral therapies (HAART) on the HIV epidemic are included. The modelled results are in broad agreement with the literature estimates and observed data. The long-term effects of HAART are also discussed.

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Eddowes, Lucy A. "Interactions of HIV-1 and hepatitis C virus with iron metabolism". Thesis, University of Oxford, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.558553.

Texto completo da fonte

Resumo:

Iron is essential for almost all biological systems and its metabolism is perturbed during infection. Clinical evidence suggests that elevated iron status correlates with a poor prognosis in HIV-1 infection. Four steps of the HIV-1 life cycle are thought to be iron dependent: reverse transcription, transcription, nuclear export of mRNA and virion assembly. The HIV protein Nef downregulates the haemochromatosis protein HFE in vitro, and iron chelators can inhibit HIV-1 replication. Given the evidence that iron can affect HIV -1 disease course and replication we investigated HIV -1 replication in monocyte-derived macrophages (MDMs) from both HFE wild type and C282Y-haemochromatosis patients. Our data from multiple patients suggests that the extent of HIV -1 replication is independent of HFE genotype in MDMs. Supplementation with the iron chelator DFO and the iron salt F AC both inhibited HIV-1 replication. Infecting differentiated U937 cells as a model system to avoid person to person variation gave inconsistent results when different viral strains and-experimental conditions were used. Changes in iron distribution during HIV-1 infection may be mediated by hepcidin. Hepcidin can be produced as part of the innate immune response which is mediated by the recognition of pathogen- associated molecular patterns (PAMPs) by a family of proteins including the Toll-like receptors (TLRs). We found that HIV-derived TLR7/8 ligands that stimulate the production ofTNFa. and IL6 in PBMCs and neutrophils does not result in a significant change in hepcidin expression whereas flagellin, a TLR5 ligand, induces TNFa., IL6 and hepcidin expression. This suggests that the changes in iron distribution may be more strongly influenced by IL6-mediated hepcidin induction in the liver or more directly by bacterial products that can cross the compromised gut mucosa during HIV-1 infection. Iron accumulation is an important eo-morbidity factor in Hepatitis C virus (HCV) infection. Chronic HCV patients have inappropriately low hepcidin expression which may explain their iron overload. Reduced hepcidin also causes the iron loading disorder hereditary haemochromatosis (HH). Genetic mutations underlying HH disrupt bone morphogenetic protein (BMP) dependent signalling pathways that control hepcidin synthesis. We investigated whether HCV was affecting the BMP/SMAD pathway, dampening down the signal for hepcidin induction, using an infectious HCV in vitro model. We found hepcidin induction by BMP6 but not BMP9 to be impaired by HCV infection. HJV, the BMP6 coreceptor, is downregulated and both SMAD6 and SMAD7 which suppress BMP signalling are upregulated in HCV infected cultures. HCV also increases expression of TNFa., and in vitro the inhibitory effect of HCV on BMP signalling can be mimicked by TNFa. In addition, supplementing cultures with an anti- TNFa. antibody restored hepcidin expression in response to BMP6. These observations were followed up in HCV patient liver biopsies from two separate cohorts. Both cohorts had lower hepcidin mRNA expression compared to a control group, consistent with other published clinical studies. HJV and ID1 mRNA was suppressed in biopsies from non-responders in the cohort with more severe disease whereas SMAD6 mRNA expression was raised in the biopsies from the cohort with mild disease. This demonstrates that the BMP/SMAD pathway can be disrupted by HCV infection and may explain the inappropriately low hepcidin expression found in vivo. Understanding the mechanism behind the hepcidin suppression found in HCV patients may suggest new therapies to prevent their iron overload thereby slowing their progression to cirrhosis and hepatocellular carcinoma.

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Schlottmann, Renate. "Zirkulierendes Interleukin-18 im Verlauf der HIV-Infektion und HIV-Hepatitis B- und C-Koinfektion". [S.l.] : [s.n.], 2004. http://deposit.ddb.de/cgi-bin/dokserv?idn=97450727X.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Razali, Karina National Centre in HIV Epidemiology &amp Clinical Research Faculty of Medicine UNSW. "Estimates and projections of HIV and Hepatitis C virus in Australia and the Asia-Pacific region". Publisher:University of New South Wales. National Centre in HIV Epidemiology & Clinical Research, 2008. http://handle.unsw.edu.au/1959.4/41095.

Texto completo da fonte

Resumo:

The use of mathematical models in studying disease epidemics can be diverse, from the focused study of the role of a single determinant of the epidemic, or to the overall estimation of morbidity and mortality. In using simple deterministic models, a balance is struck between biological and social complexities, and the high data input demands of mathematical models. This thesis aims to apply the use of deterministic mathematical models to the studies of HIV and hepatitis C epidemiology in the Asia-Pacific region. In Australia, about 85% of reported HIV cases are among homosexual men. Casual homosexual partnerships made up 40% of incident HIV cases in 1995 increasing to 65% in 2004. In the state of New South Wales, it was estimated that over 7,500 people were living with HIV/AIDS in 2005, increasing to over 10,000 by 2016 with existing levels of intervention. Intervention measures were estimated to have prevented some 44,500 cases, the majority being among injecting drug users through the Needle and Syringe Programmes. Models for the HIV epidemics in developing countries were also developed incorporating multiple routes of HIV transmission. For Papua New Guinea, it was estimated 64,000 people were living with HIV/AIDS in 2005, rising to over 500,000 by 2025 with current levels of intervention. High levels of interventions, in particular increased condom use, will be required to achieve a stabilisation or reduction in HIV prevalence. In East Timor, the HIV epidemic is still in the early stages with 138 people estimated to be living with HIV/AIDS, rising to 5,000 by 2025 with minimal intervention. For HCV, models of the epidemic in Australia showed HCV incidence peaking in 1999, followed by a decline reaching 9,700 incident cases in 2005. Of 197,000 estimated chronic HCV cases in 2005, 58% had stage F 0/1 liver disease, 15% F 2/3 liver disease, and 2% HCV-related cirrhosis. Models estimated 210 and 105 people developed HCV-related liver failure and hepatocellular carcinoma, respectively. Comparisons of modelled HCV long-term sequelae projections with linkage data showed relatively good agreement, despite discrepancies in liver-related deaths. To decrease the number of chronic HCV, at least a tripling of treatment coverage would be required. These models provide estimates of the current levels of epidemics as well as projections of future scenarios under different intervention strategies, which have an important role in the planning of strategies, as well as assessment of previous epidemic conditions.

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Matsukura, Motoi. "Highly active anti-retroviral therapy and liver mitochondrial toxicity in human immunodeficiency virus / hepatitis C virus co-infection". Thesis, University of British Columbia, 2008. http://hdl.handle.net/2429/2517.

Texto completo da fonte

Resumo:

Background: A third of HIV-infected patients are co-infected with HCV in the developed world, and more of co-infected patients than ever before are dying because of liver related diseases today. Drug-related hepatotoxicity is a growing concern among human immunodeficiency virus (HIV) / hepatitis C virus (HCV) co-infected population. Nucleotide analogues containing HIV antiretroviral therapy, namely highly active anti-retroviral therapy (HAART), can induce mitochondrial toxicity. However, little is known about the effect of nucleotide analogues on the liver at the cellular and molecular level, and how it may affect treatment. Objective: To investigate whether liver tissue from HIV/HCV co-infected individuals will show greater liver mitochondrial toxicity if currently receiving antiviral HIV medication, compared to those who are not taking it. Methods: Liver biopsies were collected from 23 HIV/HCV co-infected males. Fourteen patients were on stable HAART (ON-HAART) and 9 were OFF-HAART, including 4 who stopped HAART >6 months prior and 5 who were HAART-nave. Liver mitochondrial toxicity was assessed by transmission electron microscopy-based quantitative stereological analyses of hepatocyte and mitochondrial morphometry, as well as by mitochondrial DNA (mtDNA) and mtRNA (COX1/(ß-actin) real-time-PCR quantification. Results: Hepatocytes tended to be larger in the ON-HAART group than in the OFF-HAART group (p=0.05), but they both showed similar mitochondrial volume fraction of the cell and mitochondrial crista density. Liver mtDNA and mtRNA levels were not significantly differentbetween ON-HAART and OFF-HAART. Hepatocyte lipid accumulation was significantly higher in HCV genotype 3 compared to genotype 1 infection ()=0.002), but was not associated with HAART status. Conclusions: We found no evidence or trend of increased mitochondrial toxicity in HIV/HCV co-infected individuals currently on HAART compared to those who are not. This finding could be relevant to the decision-making process with respect to initiating HCV therapy in this population.

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Araújo, Evaldo Stanislau Affonso de. ""Estudo da cinética viral do vírus da hepatite C em pacientes co-infecatados com o HIV"". Universidade de São Paulo, 2006. http://www.teses.usp.br/teses/disponiveis/5/5134/tde-22032006-102746/.

Texto completo da fonte

Resumo:

Vinte e seis pacientes portadores de Hepatite C crônica e co-infectados pelo HIV, sem outras causas para hepatopatia e virgens para a terapia do VHC, foram tratados com Interferon Peguilado Alfa 2a de 40 KDa associado a Ribavirina por 48 semanas. Coletamos 20 amostras - horas 0, 4, 8, 12, 18, 24, 30, 36, 42, 48, dias 3, 4,7, 8, 15, 22, 29, 43, 57 e semana 12 - para quantificação do HCV (TaqMan®) e do HIV após o início da terapia. Os dados basais evidenciavam que o Genótipo 1 correspondia a 15 pacientes, enquanto o Genótipo 3 a 11. A mediana do VHC foi de 1.285.000 UI/ml, CD4 médio 573/mm3 e a média da carga viral do HIV 1109 cp/ml. Em uma análise por intenção de tratamento, o percentual obtido de resposta virológica sustentada (RVS) foi 26,9%. A única correlação estatisticamente significativa entre as variáveis analisadas e parâmetros cinéticos calculados, e a obtenção de RVS ocorreu entre RVS e Genótipo 3 (p < 0,04). Houve ajuste para os parâmetros cinéticos calculados para 18 pacientes. Pacientes com RVS apresentaram maiores taxas de eficiência do Interferon, eliminação de células infectadas e eliminação de vírions livres, assim como as Fases 1 e 2 foram mais rápidas entre eles. A ausência de redução do VHC de um log10 em 24 ou 48 horas, obteve um VPN de 100% para RVS. Ausência de queda de dois log10 nos dias oito e 29 obteve VPN de 92,31% e 100%, havendo associação entre a presença dessa resposta virológica precoce (RVP) e a obtenção de RVS (p=0,003 e p=0,01). A cinética viral mostra-se uma ferramenta útil no manejo clínico e predição muito precoce da ausência de RVS, o que é muito importante, particularmente para os co-infectados com o HIV, ante o complexo manuseio clínico dessa situação.
Twenty six co-infected patients were treated with PegIFN A2A and Ribavirin for 48 weeks. Twenty samples were drew at hours 0, 4, 8, 12, 18, 24, 30, 36, 42, 48, days 3, 4, 7, 8, 22, 29, 43, 57 and week 12 to HIV and HCV (TaqMan®) quantification after began medication. Basal data showed Genotype 1 in 15 patients, 3 in 11. Median HCV were 1.285.000 UI/ml, mean CD4 573/mm3 and mean HIV 1109 cp/ml. SVR was associated only with Genotype 3 (p<0,04). Overal SVR (ITT) were 26,9%. We obtained fitted viral kinetics parameters for 18 patients. Patients with SVR showed higher Interferon efficacy, infected cells clearance, free virion clearance and faster phase 1 and 2. Reduction on HCV load of less than one log10 at 24 or 48 hs had a NPV of 100% for SVR. Less than two log decay at days 8 and 29 had 92,31 and 100% of NPV and the presence of those reduction were associated with SVR p=0,003 and p=0,01). Viral kinetics are an important tool regarding clinic management and very early prediction of absence of SVR, wich is very important for the HIV co-infected patients for whom the clicical management is very complex.

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Vilar, Fernando Crivelenti. "Expressão do HLA-G no tecido hepático de pacientes coinfectados com HIV/HCV". Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/17/17138/tde-24082014-194222/.

Texto completo da fonte

Resumo:

A doença hepática crônica causada pelo vírus da hepatite C (HCV) tornou-se, nos últimos anos, uma das principais comorbidades dos pacientes portadores do vírus da imunodeficiência humana (HIV) nos países desenvolvidos. Os pacientes coinfectados com HIV/HCV apresentam uma progressão mais rápida para a cirrose e as suas complicações que os pacientes monoinfectados com HCV. Embora os mecanismos responsáveis por esta evolução não estejam totalmente esclarecidos, a expressão da molécula de HLA-G, um HLA de classe Ib não clássico, que tem propriedades bem reconhecidas na regulação negativa da resposta imune, pode estar relacionada à progressão da doença hepática. Os objetivos deste trabalho foram analisar o perfil de expressão de HLA-G em tecido hepático de pacientes coinfectados HIV/HCV e identificar possíveis variáveis do hospedeiro, do HCV e do HIV que possam estar relacionadas com a expressão de HLA-G na biópsia hepática. Para isso, 57 amostras de biópsia hepática de pacientes coinfectados com HIV/HCV, nas quais a imuno-histoquímica para HLA-G foi realizada, foram analisadas retrospectivamente quanto à expressão desta molécula no tecido hepático. Avaliaram-se também outras características histopatológicas da biópsia como grau de fibrose, atividade inflamatória, deposição de ferro e gordura. Determinou-se o polimorfismo de inserção ou deleção de 14 pares de bases da região 3` não traduzida do exon 8 do gene do HLA-G, que está relacionada com a produção de RNA-mensageiro, em 43 destes pacientes, além do polimorfismo de IL-28B, relacionado com a resposta ao tratamento do HCV, em 44 deles. Características bioquímicas e virológicas, tanto do HIV quanto do HCV também foram avaliadas. O genótipo 1 do HCV foi o mais prevalente (87,75%), especialmente o subgenótipo 1a (60%). A expressão do HLA-G foi observada em 38 (66,7%) amostras de fígado, e foi mais frequente em estágios moderados e severos de fibrose do que em estágios mais leves (94,1% x 55%, P < 0,01). Não houve relação entre a expressão do HLA-G e os outros parâmetros estudados. Embora a progressão para a cirrose no contexto da coinfecção por HIV/ HCV seja um processo complexo, modulado por muitos factores, a associação da intensidade de fibrose com a expressão do HLA-G pode indicar que a expressão desta proteína desempenha um importante papel nos mecanismos que contribuem para a progressão da doença, por meio da regulação negativa da resposta imune contra o HCV na coinfecção pelo HIV.
Chronic liver disease induced by hepatitis C virus (HCV) infection has recently become one of the most common comorbidities in patients who are infected with the human immunodeficiency virus (HIV) in developed countries. HIV/HCV coinfected patients show faster progression to cirrhosis and its complications than the HCV monoinfected patients. Even though the responsible mechanisms for this evolution have not been entirely clarified yet, the expression of the HLA-G molecule, a HLA from the non-classic Ib class, with well-known properties of negatively regulating the immune response, may be related to the liver disease progression. The aims of the present work were to analyze the HLA-G expression profile in the liver micro ambience of HIV/HCV coinfected patients and to identify possible host factors, HIV or HCV, that may be related to the HLA-G expression on the liver biopsy. For this purpose, 57 liver biopsies of HIV/HCV coinfect patients, in which immunohistochemistry for HLA-G had been performed, were retrospectively analyzed according the HLA-G expression on the hepatic tissue. Other histopathological features in the liver biopsies, such as fibrosis degree, inflammatory activity, iron deposition and fat were also evaluated. The polymorphism of insertion or deletion in 14-base pairs of the 3`non-translated region of exon 8 of the HLA-G gene, which is related to the production of HLA-G messenger RNA, was evaluated in 43 of the patients. Also, the polymorphism of IL-28B, related to the response to HCV treatment, was evaluated in 44 of them. Biochemical and virological features of HIV and HCV were also evaluated. The HCV genotype 1 was the most prevalent (87.75%), especially the subgenotype 1a (60%). The expression of HLA-G was observed in 38 (66.7%) samples of the liver biopsies, and it was most frequent in moderate and severe stages of fibrosis than in the mild stages (94.1% x 55%, P < 0.01). There was no established relationship between HLA-G and other parameters studied. Although the progression to cirrhosis in the context of HIV/HCV coinfection is a complex process modulated by many factors, the association of HLA-G expression with the intensity of the liver fibrosis may indicate the protein expression play an important role in the mechanisms that contribute to the progression of the disease, through the negative regulation of the immune response against HCV setting of a coinfection with HIV.

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Page, Emma. "Microbial translocation, immune activation and liver fibrosis in HIV/hepatitis C coinfection". Thesis, Imperial College London, 2013. http://hdl.handle.net/10044/1/11150.

Texto completo da fonte

Resumo:

Reasons for the accelerated progression of liver fibrosis in HIV-1/HCV coinfection are not well defined. Increased microbial translocation and/or immune activation may play a role. The aim of this research was to investigate the relationship between Th17 and Th22 cells with microbial translocation, immune activation and liver fibrosis in HIV-1/HCV coinfection. HIV-1 infection led to a preferential reduction in peripheral Th17 and Th22 cells and a reduction in Th17:Treg and Th22:Treg cell ratios. There was a negative correlation between Th17 and Th22 frequencies, Th17:Treg and Th22:Treg ratios with markers of microbial translocation and immune activation. In addition we found significant increases in the activity of the enzyme IDO, which promotes CD4 Treg development at the expense of Th17 cells. Alterations in the distribution of Th17, Th22 and Treg cells may be a mechanism through which immune activation promotes fibrogenesis. HIV-1/HCV coinfection led to increased immune activation and microbial translocation. There was a more marked depletion of Th17 cells than in HIV-1 monoinfection, and reduced Th22 cells, Th17:Treg ratio and Th22:Treg ratio, which were not seen in HCV monoinfection. Unlike HCV monoinfection there was no increase in Th1 cells in HIV-1/HCV coinfection. There was a stronger association between reduction in Th17:Treg, Th22:Treg ratios and markers of immune activation and microbial translocation in patients with HIV-1/HCV coinfection compared to HCV monoinfection. Th1 cells displayed robust negative correlations with immune activation in HIV-1/HCV coinfection, but not in HCV monoinfection. There was no association between alterations in CD4 T cell subsets and liver fibrosis in HCV monoinfection. In HIV-1/HCV coinfection reduced Th17 cell and depleted Th1 responses were associated with liver fibrosis. Our research implicates HIV-1 driven depletion of Th1 and Th17 cells in the development of liver fibrosis in HIV-1/HCV co-infection.

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Massolini, Viviam Milanez. "Avaliação de polimorfismos genéticos na progressão da infecção de pacientes monoinfectados e coinfectados com os Vírus da Imunodeficiência Humana (HIV) e Vírus da Hepatite C (VHC) /". Botucatu, 2015. http://hdl.handle.net/11449/132637.

Texto completo da fonte

Resumo:

Orientador: Maria Inês de Moura Campos Pardini
Coorientador: Rejane Maria Tommasini Grotto
Banca: Alexandre Naime Barbosa
Banca: Atila Iamarino
Resumo: A vulnerabilidade humana à infecção pelo HIV não é uniforme, fatores virológicos e do hospedeiro são determinantes no risco da transmissão e na evolução natural da infecção. Polimorfismos (do hospedeiro) nos genes KIR estão sendo associados à evolução da infecção pelo vírus. Vários estudos vêm sendo realizados em monoinfectados pelo HIV-1, mas pouco se conhece a respeito da relação desses polimorfismos em coinfecção HIV/VHC. A finalidade deste estudo foi analisar a evolução da infecção pelo HIV em pacientes coinfectados HIV/VHC, baseada em parâmetros clínicos, laboratoriais e virológicos, correlacionando polimorfismos de genes KIR. Foram incluídas no estudo 251 amostras, as quais foram distribuídas em três grupos (Grupo 1: 100 indivíduos monoinfectados HIV-1; Grupo 2: 100 indivíduos monoinfectados VHC e Grupo 3: 51 coinfectados HIV/VHC. As determinações dos subtipos (HIV-1) e genótipos (VHC) foram realizadas por sequenciamento. As definições dos polimorfismos dos genes KIR foram determinados por PCR-SSP e do HLA, por sequenciamento. Dados referentes à evolução da infecção pelo HIV-1 e VHC foram analisados a partir dos prontuários médicos dos pacientes. Os resultados obtidos pelo presente estudo com relação aos genes KIR, 2DL2, 2DS2 e 2DL5, sugerem em caráter inédito a correlação destes polimorfismos com a evolução da infecção pelo VHC em indivíduos coinfectados. A inexistência de correlação dos polimorfismos dos genes KIR com a progressão da infecção pelo HIV-1 em coinfectados sugere que nesta condição, a presença do HIV-1 pode estar influenciando muito mais a progressão da doença pelo VHC do que o desenvolvimento de aids propriamente dito
Abstract: Human vulnerability to HIV infection is not uniform, virological and host factors are determinants on the risk of transmission and natural infection progression. KIR genes polymorphisms have been being associated with progression of HIV infection. Several studies have been performed in mono-infected by HIV-1, but few knwoledge is known about the relation of these polymorphisms in coinfection by HIV/HCV. The purpose of this study was to assess the increasing of the infection by HIV in patients coinfected HIV/HCV, based on clinical, laboratory and virological parameters and correlating KIR genes polymorphisms. The study included 251 samples which were divided into three groups (Group 1: 100 HIV mono-infected; Group 2: 100 mono-infected HCV; Group 3: 51 Co-Infected HIV/HCV). Determination of subtypes (HIV) and genotypes (HCV) was held using RNA sequencing. Polymorphisms definitions of KIR genes were determined by PCR-SSP and HLA were accomplished out by sequencing. Clinical and laboratory data, regarding the evolution of HIV and HCV infection were analyzed from the medical records of patients. The results obtained by this study concerning KIR, 2DL2, 2DL5 and 2DS2 genes demonstrate the state-of-the-art on the correlation of these polymorphisms with evolution of HCV infection in coinfected individuals. The absence of correlation between the polymorphism of KIR genes with progression of HIV-1 infection in co-infected, suggests that in this particular condition, the presence of HIV-1 may influence much more the disease progression by the HCV than the aids development in itself
Mestre

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Jung, Dorothy Eunhyun. "CD4+ T cell discordance in HIV-infected patients with and without hepatitis C virus (HCV)-coinfection". Thesis, Boston University, 2012. https://hdl.handle.net/2144/31572.

Texto completo da fonte

Resumo:

Thesis (M.A.)--Boston University
PLEASE NOTE: Boston University Libraries did not receive an Authorization To Manage form for this thesis or dissertation. It is therefore not openly accessible, though it may be available by request. If you are the author or principal advisor of this work and would like to request open access for it, please contact us at open-help@bu.edu. Thank you.
HIV infected patients with hepatitis C virus (HCV) infection are at increased risk of faster fibrosis progression and end-stage liver disease compared to patients with HCV alone. Why HIV /HCV -coinfected patients progress more rapidly to advanced liver disease is unknown, though several studies suggest that HIV -related immunosuppression may play a role. We have recently shown that low absolute CD4+ counts are also prevalent in patients with liver cirrhosis who are HIV seronegative. Furthermore, HIV seronegative cirrhotic patients with low absolute CD4+ counts have normal CD4+ percentages. This CD4+ "discordance" among patients with liver disease points towards an alternate mechanism for low CD4 T cell counts, other than HIV-induced immunosuppression. In this retrospective study, we compared the prevalence of CD4 Tcell discordance in HIV/HCV-coinfected patients and patients with HIV alone. We also examined clinical and laboratory exam findings associated with this discordant profile. We show that discordance between absolute CD4 counts and CD4 T -cell percentages was significantly associated with HIV/HCV-coinfection as well as leucopenia. We also found that a physical exam finding of hepatomegaly, splenomegaly, and/or spider angiomata as well as certain laboratory markers of advanced liver disease (eg, AST/ALT > 1) may be associated with CD4 T-cell discordance. We conclude that among patients co infected with HIV and HCV, CD4+ discordance may be an important screening tool in patients with possible underlying liver disease. Low CD4+ counts in these patients may correlate not only with advanced HIV immunosuppression, but may indicate underlying liver disease when accompanied by a normal CD4+ percentage.
2031-01-01

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Asplid, Matilda, Ponce Gabriela Becerra e Ponce Paula Becerra. "Att leva med en smittsam blodsjukdom". Thesis, Högskolan i Halmstad, Akademin för hälsa och välfärd, 2018. http://urn.kb.se/resolve?urn=urn:nbn:se:hh:diva-38648.

Texto completo da fonte

Resumo:

Humant immunbristvirus (HIV), hepatit B och C är blodsmittor som finns världen över. Dessa tre sjukdomar anses som allmänfarliga och som anmälningspliktiga sjukdomar. Livet med en smittsam blodsjukdom kan vara påfrestande för en patient, både fysiskt och psykiskt. Syftet med denna litteraturstudie var att beskriva patienters upplevelse av att leva med en smittsam blodsjukdom. Studien är en allmän litteraturstudie, där kvalitativ forskning användes för att få fram resultatet. Resultatet består av tre teman och sju subteman. De teman som skapades var: rädsla, känslan av att vara osedd och känslan av att vara sedd. Livet med en smittsam blodsjukdom kan vara påfrestande för en patient. Rädslan för sjukdomens konsekvenser är stor. Socialt stöd från anhöriga och sin omgivning har stor påverkan på patientens liv. Brist på socialt stöd kan bidra till att patienten drar sig undan, tar till alternativa hjälpmedel såsom alkohol och narkotika samt till att patienten utvecklar depression. Som vårdpersonal är det viktigt att se patienten bakom den smittsamma blodsjukdomen, då patienter ibland upplever mötet med sjukvården som något negativt. Vårdpersonalen som är rädda för sjukdomen, är även rädda för att bli smittade. Det bidrar till att patienten känner sig dömd och väljer att avstå från behandlingar.
Human immunodeficiency virus (HIV), hepatitis b and c are contagious blood diseases that exists worldwide. These three diseases are considered to be generally dangerous and as a notifiable disease. Living with a contagious blood disease can be stressful to patients both physically and mentally. The purpose of this literature study was to describe patients' experience of living with contagious blood diseases. The study is a general literature study, where qualitative research was used to produce the result. The result consists of three themes and seven different subthemes. That resulted in the creation of three themes: fear, the feeling of being unseen and the feeling of being seen. Living with a contagious blood disease can be stressful to a patient. There is a great fear for the consequence of the disease. Getting social support from relatives and their social environment has a major impact on the patient's life. The lack of social support can make the patient avoid social contact. Patients’ take alternative means such as alcohol, drugs and the patient can develop depression. As a formal caregiver it is important to see the person behind the infection, as the patient experience the meeting with formal caregivers as negative. The formal caregivers are afraid of the disease and to be infected. The patient feels judged and chooses to avoid treatment.

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Gonzalez, Mario Peribañez. "Prevalência de hipovitaminose D e fatores de risco associados em pacientes portadores de HIV, HCV e coinfecção HIV/HCV na cidade de São Paulo". Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/5/5168/tde-09032017-115725/.

Texto completo da fonte

Resumo:

Introdução e Objetivos: Hipovitaminose D, definida como nível sérico de 25(OH)D insuficiente é considerada pandêmica em muitas populações ao redor do mundo e está associada a comorbidades em hepatite C, infecção por HIV e coinfecção HIV/HCV. Os objetivos deste estudo são: 1) comparar a prevalência de deficiência de vitamina D (DVD) caracterizada por nível sérico de 25(OH)D < 20 ng/mL, entre pacientes monoinfectados pelo HCV, monoinfectados pelo HIV, coinfectados HIV/HCV e participantes do grupocontrole; 2) identificar fatores de risco específicos associados com DVD na população estudada. Pacientes e Métodos: Foram coletados dados clínicos e demográficos, 25(OH)D sérica, testes de função hepática e perfil metabólico durante os meses de inverno de 129 pacientes HCV monoinfectados, 118 pacientes HIV monoinfectados e 53 pacientes coinfectados HIV/HCV tratados em centros de referência na cidade de São Paulo, bem como, em 122 indivíduos saudáveis de um grupo-controle formado de pessoas não infectadas por HIV, HCV ou HBV, sem uso de suplementos de vitamina D. Resultados: A prevalência de deficiência de vitamina D ajustada por sexo, idade ( = 50), cor de pele (branco vs não branco), índice de massa corporal ( = 25), colesterol total (= 200), fração HDL colesterol ( = 40 em homens = 50 em mulheres), triglicérides (= 150), glicemia ( = 110), uso de efavirenz (sim vs não), uso de tenofovir (sim vs não) e índice HOMA-IR, foi menor no grupo HCV do que no controle e no grupo HIV (p < 0.001). Em todos os grupos, a razão de chance de DVD aumenta 1.21 [IC95%(1.01; 1.44) p=0.026] para cada ponto de aumento do índice HOMA. Efavirenz também esteve associado com maior razão de chance de DVD [3.49(IC95% 1.14-10.67) p=0.028]. Análise por regressão logística simples foi aplicada para avaliar fatores de risco associados a DVD dentro de cada grupo. Nesta análise, resultaram com associação significativa o sexo masculino, com uma menor razão de chance para DVD [RC 0,42(IC95% 0,18 - 0,96) p = 0,04] no grupo-controle e no grupo HCV [RC 0,42(IC95% 0,2 - 0,88) p = 0,02]; ainda no grupo HCV houve associação significativa entre DVD e HOMA-IR elevado [RC 5,59(IC 95% 1,37 - 22,8) p = 0,02]; e, no grupo HIV, os indivíduos que apresentaram nadir histórico de CD4 maior que 200 células/mm3 tiveram menos chance de DVD [RC 0,41 (IC95% 0,18 - 0,95) p = 0,04]. Conclusão: Uma alta prevalência de DVD foi observada em toda a população estudada, incluindo o grupo-controle, sugerindo que a apresentação de infecção por HIV e/ou HCV por si só não aumenta as chances de DVD. Por outro lado, o incremento do índice HOMA e o uso de efavirenz se destacaram como fatores de risco nesta população. Estes achados ressaltam a importância da associação da deficiência de vitamina D com outras duas condições; a resistência à insulina e o uso de terapia antirretroviral para o HIV, os quais, isoladamente ou em combinação, podem aumentar a incidência de comorbidades como o diabetes do tipo 2
Background and Aims: Hypovitaminosis D, defined as insufficient serum level of 25(OH)D, is considered pandemic in many populations worldwide and is associated with co-morbidities in hepatitis C, HIV and HIV/HCV co-infection. The aim of this study is to 1) compare the prevalence of 25-hydroxyvitamin D deficiency (VDD), defined as serum levels of 25(OH)D < 20 ng/mL, among HCV mono-infected, HIV mono-infected, HIV/HCV co-infected patients and control participants and 2) identify specific risk factors associated with VDD in each group. Patients and Methods: We collected demographic and clinical data, serum 25-hydroxyvitamin D, liver function parameters and metabolic profiles on 129 HCV mono-infected, 118 HIV mono-infected and 53 HIV/HCV co-infected patients treated at reference centers in São Paulo (Brazil) as well as on 122 volunteer controls, not infected by HIV, HCV, HBV or taking vitamin D supplements. Results: VDD prevalence adjusted for sex, age ( = 50), skin color (white vs not white), body mass index ( = 25), total cholesterol (= 200), HDL cholesterol ( = 40 in men and = 50 in women), triglycerides ( = 150), glycemia ( = 110), use of Efavirenz - EFV (yes vs no), use of Tenofovir -TDV (yes vs no) and HOMA-IR was lower in HCV group than control and HIV groups (p < 0.001). In all groups, adjusted odds of VDD increases by 1.21 [CI95% (1.01-1.44)] for each unit increase of HOMA-IR. Antirretroviral therapy regimens containing efavirenz were also associated to higher odds of VDD 3.49 [CI95% (1.14-10.67) p=0.028]. Logistic regression was applied to analyze risk factors associated to VDD within each group. In this analysis male sex resulted significantly associated to lower chance of VDD [OR 0,42(CI95% 0,18 - 0,96) p = 0,04] in control group and in HCV group [RC 0,42(CI95% 0,2 - 0,88) p = 0,02]; still in HCV group, elevated HOMA-IR was significantly associated to VDD [OR 5,59(CI 95% 1,37 - 22,8) p = 0,02]; and in HIV group, individuals presenting CD4 nadir higher than 200 cells/mm3 had less chance of VDD [OR 0,41 (IC95% 0,18 - 0,95) p = 0,04]. Conclusion: High prevalence of VDD was observed across all studied population, including control group, suggesting that being infected with HIV and/or HCV per se does not increase the chance of VDD. Otherwise, VDD was positively associated with HOMA-IR increase for controls and infected patients. It is also associated to use of Efavirenz in HIV/HCV patients. This finding highlights the relevance of vitamin D deficiency association with two other conditions; insulin resistance and antiretroviral therapy, which isolated or in combination, may contribute to the incidence of comorbidities, as Type 2 diabetes mellitus

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Picelli, Natália [UNESP]. "Coinfecção pelos vírus da hepatite C (VHC) vírus da imunodificência humana (HIV): polimosrfismo dos sistemas HPA -1, -3, 3 e -5". Universidade Estadual Paulista (UNESP), 2013. http://hdl.handle.net/11449/92140.

Texto completo da fonte

Resumo:

Made available in DSpace on 2014-06-11T19:25:36Z (GMT). No. of bitstreams: 0 Previous issue date: 2013-02-19Bitstream added on 2014-06-13T18:29:07Z : No. of bitstreams: 1 000750960.pdf: 2002921 bytes, checksum: f29767a903b7bf0ec9f1ce7ee7c7c5af (MD5)
Além de fatores virais e do hospedeiro a progressão da fibrose hepática resultante da infecção pelo Vírus da Hepatite C (VHC) tem sido relacionada a polimorfismos genéticos do hospedeiro. Nesta linha, recentemente polimorfismos dos Antígenos Plaquetários Humanos (HPA) foram associados à progressão para fibrose em pacientes monoinfectados pelo VHC. Alguns destes antígenos HPA residem em proteínas da família das integrinas, cuja expressão, também, já foi associada à progressão da fibrose hepática. No entanto, estudos relacionando polimorfismos genéticos do hospedeiro em pacientes coinfectados com o VHC e o Vírus da Imunodeficiência Humana (HIV) são raros e, não há nenhum estudo relacionando polimorfismos HPA com progressão para fibrose. Assim, o objetivo deste estudo foi avaliar possíveis associações dos polimorfismos dos sistemas HPA-1, -3 e -5, que residem em integrinas, na progressão da fibrose hepática em indivíduos coinfectados VHC/HIV. DNA Genômico de 56 pacientes coinfectados VHC/HIV foi utilizado como fonte para genotipagem dos sistemas HPA -1 e -3 por PCR-SSP, e HPA -5 por PCR-RFLP. Progressão da fibrose foi avaliada utilizando o escore de METAVIR, sendo constituídos dois grupos: Grupo 1 (G1): pacientes coinfectados VHC/HIV com baixo grau de fibrose (F1, fibrose portal sem septos ou F2, com poucos septos) e Grupo 2 (G2): pacientes coinfectados VHC/HIV com fibrose avançada (F3, numerosos septos ou F4, cirrose). Um grupo controle, do estudo de Silva e colaboradores (2012), constituído por pacientes monoinfectados pelo VHC com baixo grau de fibrose (F1 ou F2) e fibrose avançada (F3 ou F4) foi utilizado para as análises realizadas neste estudo. O Teste Exato de Fisher foi utilizado para avaliar possíveis associações entre o polimorfismo dos sistemas HPA -1, -3 e -5 e a progressão para fibrose, utilizando um nível de significância de 5%. Não houve desvio do equilíbrio...
To evaluate the associations of Human Platelet Antigen (HPA) polymorphisms -1, -3 and -5 with HIV/HCV coinfection. In this study were included 60 HIV/HCV-coinfected patients from the Sao Paulo State health service centers. Data reported by Verdichio-Moraes et al (2009) were used as the non-infected and HCV monoinfected groups to evaluate the association of HPA -1, -3 and -5 in HIV/VHC coinfected patients. HPA genotyping was performed in 60 HIV/HCV coinfected patients by PCR-SSP or PCR-RFLP. HIV subtyping and HCV genotyping was performed by RT-PCR followed sequencing. The data analyses were performed using the c2 test or Fisher’s Exact Test and the logistic regression model. HIV/HCV coinfected patients presented HCV either genotype 1 (78.3%) or non-1 (21.7%) and HIV either subtype B (85.0%) or non-B (15%). The HPA-1a/1b genotype was more frequent (p<0.05) in HIV/HCV coinfection than in HCV monoinfection and the allelic frequency of HPA-5b in the HIV/HCV coinfected patients was lower (P<0.05) than in HCV monoinfected cases and non-infected individuals. These data suggest that HIV presence may have influenced the interaction of HCV with platelets. On the other hand, HPA-5a/5b was more frequent (p<0.05) in HIV/HCV coinfected and HCV monoinfected groups than in the non-infected individuals, suggesting that this platelet genotype is related to HCV infection, regardless of HIV presence. Results suggest that the HPA profile in HIV/HCV coinfected individuals differs from the one of both HCV monoinfected and non-infected population. So, the HPA polymorphism can be a genetic marker associated with HIV/HCV coinfection

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Picelli, Natália. "Coinfecção pelos vírus da hepatite C (VHC) e vírus da imunodeficiência humana (HIV) : polimorfismo dos sistemas HPA -1, -3, e -5 /". Botucatu, 2013. http://hdl.handle.net/11449/92140.

Texto completo da fonte

Resumo:

Orientador: Maria Inês de Moura Campos Pardini
Coorientador: Rejane Maria Tommasini Grotto
Banca: Fernando Gomes Romeiro
Banca: João Pessoa Araujo Junior
Resumo: Além de fatores virais e do hospedeiro a progressão da fibrose hepática resultante da infecção pelo Vírus da Hepatite C (VHC) tem sido relacionada a polimorfismos genéticos do hospedeiro. Nesta linha, recentemente polimorfismos dos Antígenos Plaquetários Humanos (HPA) foram associados à progressão para fibrose em pacientes monoinfectados pelo VHC. Alguns destes antígenos HPA residem em proteínas da família das integrinas, cuja expressão, também, já foi associada à progressão da fibrose hepática. No entanto, estudos relacionando polimorfismos genéticos do hospedeiro em pacientes coinfectados com o VHC e o Vírus da Imunodeficiência Humana (HIV) são raros e, não há nenhum estudo relacionando polimorfismos HPA com progressão para fibrose. Assim, o objetivo deste estudo foi avaliar possíveis associações dos polimorfismos dos sistemas HPA-1, -3 e -5, que residem em integrinas, na progressão da fibrose hepática em indivíduos coinfectados VHC/HIV. DNA Genômico de 56 pacientes coinfectados VHC/HIV foi utilizado como fonte para genotipagem dos sistemas HPA -1 e -3 por PCR-SSP, e HPA -5 por PCR-RFLP. Progressão da fibrose foi avaliada utilizando o escore de METAVIR, sendo constituídos dois grupos: Grupo 1 (G1): pacientes coinfectados VHC/HIV com baixo grau de fibrose (F1, fibrose portal sem septos ou F2, com poucos septos) e Grupo 2 (G2): pacientes coinfectados VHC/HIV com fibrose avançada (F3, numerosos septos ou F4, cirrose). Um grupo controle, do estudo de Silva e colaboradores (2012), constituído por pacientes monoinfectados pelo VHC com baixo grau de fibrose (F1 ou F2) e fibrose avançada (F3 ou F4) foi utilizado para as análises realizadas neste estudo. O Teste Exato de Fisher foi utilizado para avaliar possíveis associações entre o polimorfismo dos sistemas HPA -1, -3 e -5 e a progressão para fibrose, utilizando um nível de significância de 5%. Não houve desvio do equilíbrio ...
Abstract: To evaluate the associations of Human Platelet Antigen (HPA) polymorphisms -1, -3 and -5 with HIV/HCV coinfection. In this study were included 60 HIV/HCV-coinfected patients from the Sao Paulo State health service centers. Data reported by Verdichio-Moraes et al (2009) were used as the non-infected and HCV monoinfected groups to evaluate the association of HPA -1, -3 and -5 in HIV/VHC coinfected patients. HPA genotyping was performed in 60 HIV/HCV coinfected patients by PCR-SSP or PCR-RFLP. HIV subtyping and HCV genotyping was performed by RT-PCR followed sequencing. The data analyses were performed using the c2 test or Fisher's Exact Test and the logistic regression model. HIV/HCV coinfected patients presented HCV either genotype 1 (78.3%) or non-1 (21.7%) and HIV either subtype B (85.0%) or non-B (15%). The HPA-1a/1b genotype was more frequent (p<0.05) in HIV/HCV coinfection than in HCV monoinfection and the allelic frequency of HPA-5b in the HIV/HCV coinfected patients was lower (P<0.05) than in HCV monoinfected cases and non-infected individuals. These data suggest that HIV presence may have influenced the interaction of HCV with platelets. On the other hand, HPA-5a/5b was more frequent (p<0.05) in HIV/HCV coinfected and HCV monoinfected groups than in the non-infected individuals, suggesting that this platelet genotype is related to HCV infection, regardless of HIV presence. Results suggest that the HPA profile in HIV/HCV coinfected individuals differs from the one of both HCV monoinfected and non-infected population. So, the HPA polymorphism can be a genetic marker associated with HIV/HCV coinfection
Mestre

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

Roos, Hampus, e Martin Lidholm. "Hur patienter med blodburen smitta upplever vårdpersonalens attityd mot dem". Thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-397986.

Texto completo da fonte

Resumo:

Bakgrund: De tre vanligaste blodburna smittor som vårdpersonalen träffar på är humant immunbristvirus (HIV), hepatit C samt hepatit B. Dessa sjukdomar sprider sig via blodprodukter och medför en risk att vårdpersonalen kan bli smittade i sitt arbete. Risk för stigmatisering hos vårdpersonalen finns då sjukdomarna ofta förknippas med homosexualitet och intravenöst drogmissbruk. Risken är att patienter upplever sig diskriminerade av vårdpersonalen och att det påverkar omvårdnaden. Syfte: Syftet var att undersöka vårdpersonalens attityd mot patienter med blodburen smitta samt patienters upplevelse av vården och omvårdnaden. Metod: En litteraturstudie bestående av sex kvantitativa artiklar, fyra kvalitativa artiklar samt två mix-metod artiklar där det gjordes en induktiv analys av artiklarna för att tolka resultatet. Resultat: Det existerar en stigmatiserande attityd hos viss vårdpersonal mot patienter med blodburen smitta. En del i vårdpersonalen känner även av en viss rädsla mot patienterna med blodburen smitta, då rädslan grundar sig i att själva bli smittade. Rädslan och den stigmatiserande attityden påverkar vårdpersonalens vilja samt trygghet att vårda patienter med blodburen smitta. Patienter upplever och känner sig diskriminerade av vårdpersonal som har en stigmatiserande attityden samt visar rädsla gentemot dem. Patienterna har då större risk att undvika vården. Det som patienter upplever bra är när de får träffa samma personal som de kan lära känna och som vet deras historia. Slutsats: Viss vårdpersonal har en stigmatiserande attityd och rädsla mot patienter med blodburen smitta och detta grundar sig i vårdpersonalens okunskap och låga utbildning. Patienter märker av och känner sig diskriminerade av vårdpersonal som visar rädsla samt en stigmatiserande attityd mot dem. Detta påverkar patienters vård då patienter undviker vården eller inte får samma vård av vårdpersonalen på grund av sin sjukdom.
Background: The three most common blood-borne pathogens that the healthcare professional encounters are human immunodeficiency virus (HIV), hepatitis C and hepatitis B. These pathogens spread through blood products and there is a risk that the healthcare staff gets infected in their work. There is a risk of stigma among healthcare professionals as the pathogens are often associated with homosexuality and intravenous drug abuse. At the same time, the risk is that patients feel discriminated by the healthcare staff and that it affects their care. Purpose: The aim was to investigate the attitudes of the healthcare professionals towards patients with blood-borne pathogens as well as patients' experience of their care and nursing. Method: A literature study was based on six quantitative articles, four qualitative articles and two mix-method articles in which an inductive analysis of the articles was performed to interpret the results. Result: There is a stigmatizing attitude among healthcare professionals towards patients with bloodborne infection. Some of the healthcare staff also feel a certain fear of the patients with blood-borne infection and the fear is based on being infected themselves. Fear and stigmatizing attitudes affect the will of the healthcare staff and the safety of caring for patients with blood-borne infection. Patients experience and feel discriminated against by healthcare professionals who have a stigmatizing attitude and fear of them. Patients are then at greater risk of avoiding care. What patients feel good about is when they get to meet the same staff they can get to know and that knows their history. Conclusion: Some healthcare professionals have a stigmatizing attitude and fear of patients with blood-borne infection and this is based on the healthcare staff's knowledge and low education. Patients notice and feel discriminated against by healthcare professionals who display fear as well as a stigmatizing attitude towards them. This affects patients' care as patients avoid the care or do not receive the same care from the care staff due to their illness. Keywords: Blood-Borne Pathogens, healthcare professionals, patient, HIV, hepatitis B & hepatits C.

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

Massolini, Viviam Milanez [UNESP]. "Avaliação de polimorfismos genéticos na progressão da infecção de pacientes monoinfectados e coinfectados com os Vírus da Imunodeficiência Humana (HIV) e Vírus da Hepatite C (VHC)". Universidade Estadual Paulista (UNESP), 2015. http://hdl.handle.net/11449/132637.

Texto completo da fonte

Resumo:

Made available in DSpace on 2016-01-13T13:27:27Z (GMT). No. of bitstreams: 0 Previous issue date: 2015-02-27. Added 1 bitstream(s) on 2016-01-13T13:32:51Z : No. of bitstreams: 1 000854163.pdf: 1976046 bytes, checksum: 9b722e3de2741fb27df9024552ccb885 (MD5)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
A vulnerabilidade humana à infecção pelo HIV não é uniforme, fatores virológicos e do hospedeiro são determinantes no risco da transmissão e na evolução natural da infecção. Polimorfismos (do hospedeiro) nos genes KIR estão sendo associados à evolução da infecção pelo vírus. Vários estudos vêm sendo realizados em monoinfectados pelo HIV-1, mas pouco se conhece a respeito da relação desses polimorfismos em coinfecção HIV/VHC. A finalidade deste estudo foi analisar a evolução da infecção pelo HIV em pacientes coinfectados HIV/VHC, baseada em parâmetros clínicos, laboratoriais e virológicos, correlacionando polimorfismos de genes KIR. Foram incluídas no estudo 251 amostras, as quais foram distribuídas em três grupos (Grupo 1: 100 indivíduos monoinfectados HIV-1; Grupo 2: 100 indivíduos monoinfectados VHC e Grupo 3: 51 coinfectados HIV/VHC. As determinações dos subtipos (HIV-1) e genótipos (VHC) foram realizadas por sequenciamento. As definições dos polimorfismos dos genes KIR foram determinados por PCR-SSP e do HLA, por sequenciamento. Dados referentes à evolução da infecção pelo HIV-1 e VHC foram analisados a partir dos prontuários médicos dos pacientes. Os resultados obtidos pelo presente estudo com relação aos genes KIR, 2DL2, 2DS2 e 2DL5, sugerem em caráter inédito a correlação destes polimorfismos com a evolução da infecção pelo VHC em indivíduos coinfectados. A inexistência de correlação dos polimorfismos dos genes KIR com a progressão da infecção pelo HIV-1 em coinfectados sugere que nesta condição, a presença do HIV-1 pode estar influenciando muito mais a progressão da doença pelo VHC do que o desenvolvimento de aids propriamente dito
Human vulnerability to HIV infection is not uniform, virological and host factors are determinants on the risk of transmission and natural infection progression. KIR genes polymorphisms have been being associated with progression of HIV infection. Several studies have been performed in mono-infected by HIV-1, but few knwoledge is known about the relation of these polymorphisms in coinfection by HIV/HCV. The purpose of this study was to assess the increasing of the infection by HIV in patients coinfected HIV/HCV, based on clinical, laboratory and virological parameters and correlating KIR genes polymorphisms. The study included 251 samples which were divided into three groups (Group 1: 100 HIV mono-infected; Group 2: 100 mono-infected HCV; Group 3: 51 Co-Infected HIV/HCV). Determination of subtypes (HIV) and genotypes (HCV) was held using RNA sequencing. Polymorphisms definitions of KIR genes were determined by PCR-SSP and HLA were accomplished out by sequencing. Clinical and laboratory data, regarding the evolution of HIV and HCV infection were analyzed from the medical records of patients. The results obtained by this study concerning KIR, 2DL2, 2DL5 and 2DS2 genes demonstrate the state-of-the-art on the correlation of these polymorphisms with evolution of HCV infection in coinfected individuals. The absence of correlation between the polymorphism of KIR genes with progression of HIV-1 infection in co-infected, suggests that in this particular condition, the presence of HIV-1 may influence much more the disease progression by the HCV than the aids development in itself

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

Yao, Felix Caspar. "Investigation on the risk of viral infection in musculoskeletal grafts". University of Western Australia. School of Surgery, 2010. http://theses.library.uwa.edu.au/adt-WU2010.0068.

Texto completo da fonte

Resumo:

[Truncated abstract] Around 50,000 hip and knee replacements are performed every year in Australia and this number has been increasing by around 13% annually since 1998 (Transplantation Society 2006). The incidence and number of revision surgery has increased by a similar proportion. Autogenous bone or allograft is still the gold standard grafting material and is currently used in a variety of reconstructive surgical procedures. The use of any allograft material carries with it the risk of transfer of disease from donor to recipient. These tissues can transmit the same viral and bacterial infections as blood, and the products of a single donation may be transplanted to several recipients. In contrast to blood, musculoskeletal tissues may come from surgical and cadaveric donation. Overall, the prevention of infection relies on the maintenance of rigid protocols for procurement, donor and allograft testing, secondary sterilisation, and the adherence to internal safety standards within the tissue banks. This thesis aims to determine the risk of viral infection among musculoskeletal tissue donors in Australia. We retrieved and analysed data retrospectively from three large tissue banks in Australia (Perth, Queensland, Victoria). This includes 12,415 musculoskeletal tissue donors, 10,937 of which are surgical donors and 1,478 of which are deceased donors, for the period of 1993 -2004. This data was analysed to determine the prevalence and incidence of viral infections such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human T-lymphotropic virus (HTLV) in musculoskeletal allografts. The results indicate that the risk of viral infection from musculoskeletal tissue transplantation in Australia is low. ... The results indicate that the overall prevalence of screened transfusion-transmitted viral infections did not vary significantly for musculoskeletal donors over the study period, despite falling in the general population and first-time blood donors. In tissue donors, HIV incidence significantly decreased over time, and HBV decreased significantly during 1999-2001; however, there was an apparent increase in the estimated incidence of HCV in 2002-2004 compared with earlier years. Furthermore the residual risk estimate of HIV in the period 2002-2004 has declined 5-fold compared to estimates in the period 1993-1995. This is perhaps due to greater awareness of high risk behaviours among donors, improvement in donor recruitment and an overall decrease in infection levels in the general population. Musculoskeletal tissue is second only to blood as the most frequent transplanted human tissue. Viral infection is a potential complication of tissue transplantation. In this thesis the rates of HIV, HBV, HCV and HTV infection in musculoskeletal donors in Australia were identified and then compared with results in published data from Canada, Scotland and the United States. The study also compared that result with first-time blood donors because they have satisfied similar donor selection criteria (Galea et al. 2006). The results indicate that prevalence and incidence estimates for viral infection in Australian tissue donors are higher than those in blood donors. This was also reported in studies from other countries. Accordingly, it is crucial that viral prevalence and incidence be monitored to evaluate the safety of tissue supply and to improve donor selection processes.

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Chen, Yang. "An Epidemiological Study of Hepatitis C Virus Infection Among U.S. Population". Digital Commons @ East Tennessee State University, 2016. https://dc.etsu.edu/etd/3105.

Texto completo da fonte

Resumo:

Hepatitis C virus (HCV) infection is the most common blood-borne infection in the United States (U.S.). The largest increases of incidence for HCV infection are reported in the Appalachian region. This study aimed to 1) examine the prevalence and trends of HCV infection in the U.S. from 1999 to 2012; 2) investigate barriers to HCV infection treatment in Northeast Tennessee and the U.S.; and 3) study characteristics and risk factors for HIV-infection and HCV-infection in Northeast Tennessee. In the U.S., data were obtained from the National Health and Nutrition Examination Survey (NHANES) 1999-2012 to study the prevalence of HCV infection and barriers to treatment. In Northeast Tennessee, hepatitis C and HIV/AIDS data were obtained from National Electronic Disease Surveillance System (NEDSS) and enhanced HIV/AIDS Reporting System (eHARS). Descriptive statistics and multiple logistic regression models were used for analysis. Odds ratios (OR) and 95% confidence intervals (CI) were reported. There was an estimated 3.8 million people having HCV antibody in the U.S. in 2012. No significant change was found in the prevalence of HCV infection during 1999 – 2012. The leading barrier to the treatment was cost issues in the U.S. (50.0%) and Northeast Tennessee (25.0%), respectively. HCV patients without symptoms in Northeast Tennessee were more likely to be untreated (OR: 3.08, 95% CI: 1.10-8.60) and patients without health insurance in the U.S. were more likely to be untreated than their counterparts (OR: 3.38, 95% CI: 1.14-10.05). The incidence of acute hepatitis C peaked in 2012-2013 in Northeast Tennessee, while the incidence of HIV/AIDS increased by 100% from 2013 to 2015. More injection drug users (IDUs) and less men who have sex with men (MSM) were observed in patients with HCV infection than in those with HIV infection (IDUs: 50.63% vs.16.38% p

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Gröner, Jan [Verfasser], e Johannes [Akademischer Betreuer] Bogner. "Mitochondriale Dysfunktion bei chronischer Hepatitis B, chronischer Hepatitis C und bei HIV-Postexpositionsprophylaxe / Jan Benedikt Gröner. Betreuer: Johannes Bogner". München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2011. http://d-nb.info/1017233004/34.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

Ogawa, Lisa Marie Fink. "Substance Use Experiences and Hepatitis C Treatment Decision-Making Among HIV/HCV Co-infected Adults: A Dissertation". eScholarship@UMMS, 2007. https://escholarship.umassmed.edu/gsn_diss/3.

Texto completo da fonte

Resumo:

Hepatitis C virus (HCV) infection affects between 150,000 to 300,000 human immunodeficiency (HIV) positive adults in the US (Alter et al., 1999; Sherman, Rouster, Chung, & Rajicic, 2002). The majority of co-infected adults (50%-90%) have acquired HCV through substance abuse (Centers for Disease Control [CDC], 1998; CDC, 2006b). A patient's decision to begin HCV treatment is not straightforward. HCV evaluation and treatment involves a significant amount of time, energy, effort, and compliance on the part of the patient. There is limited information on how adults with HCV mono-infection make decisions about HCV evaluation and treatment (Fraenkel, McGraw, Wongcharatraee, & Garcia-Tsao, 2005). Even less is known about how adults with HIV/HCV co-infection with a history of substance abuse make treatment decisions. The purpose of this study was to describe substance abuse experiences and to explore how these related to patient decision-making about HCV treatment in HIV/HCV co-infected adults. Qualitative descriptive design and secondary data analysis were used to study these phenomena. Data were managed by using NVivo software and analyzed by secondary data analysis and qualitative content analysis. Five major themes with sub-themes emerged during the data analysis. They were: (1) The Evolution of Substance Abuse (with sub-themes: substance abuse initiation, escalation, polysubstance abuse, normalcy: a family of addicts, the enemy within, and transmission and disclosure), (2) Revolving Door: Going Back Out (with sub-themes: specific events as a trigger, emotions as a trigger, alcohol as a trigger, and destructive relationships as a trigger), and (3) Reconstructing Life (with sub-themes: defining moments in substance abuse addiction and maintaining sobriety), (4) HCV Infection Treatment Issues (with sub-themes: HCV treatment: not a priority, fear, and misinformation, and desire to use stimulated during HCV treatment), and (5) Get Clean and Try It. The participants spoke about how their substance abuse evolved from inception to sobriety, and for some it remained a problem. Relapse and recovery were fragile in nature especially in these adults with HIV/HCV co-infection. The decision-making process is influenced by substance abuse experiences, however more research is needed to uncover specific factors influencing these decisions.

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Castro, Gleusa de. "Análise histológica comparativa de biópsias hepáticas de pacientes com hepatite C crônica, co-infectados pelo HIV-1, realizadas antes e após o tratamento da hepatite C". Universidade de São Paulo, 2006. http://www.teses.usp.br/teses/disponiveis/17/17138/tde-18012007-182909/.

Texto completo da fonte

Resumo:

Sabe-se que o vírus da imunodeficiência humana (HIV) pode modificar a história natural da infecção pelo HCV, acelerando a progressão da fibrose hepática e conseqüente evolução para cirrose. O tratamento com interferon-alfa pode levar à melhora da histologia hepática, reduzindo a inflamação e fibrose, principalmente nos pacientes que apresentam resposta virológica sustentada. O impacto do tratamento sobre a evolução histológica em pacientes não-respondedores ao tratamento da hepatite C apresenta resultados controversos. Objetivos: Avaliar, nos pacientes com hepatite C crônica, co-infectados pelo HIV, o impacto do tratamento da hepatite C, sobre as modificações de parâmetros indicativos de fibrose e atividade inflamatória, em biópsias de fígado realizadas antes e após o tratamento da hepatite C. Métodos: Foram estudados 26 pacientes co-infectados pelo HCV e HIV-1, submetidos à biópsia hepática antes e, em média, 25,2 meses após o término do tratamento da hepatite C. Fragmentos da biópsia hepática foram comparados, antes e após o tratamento, em relação aos seguintes parâmetros: Índice de Atividade Histológica (HAI) e o grau de Fibrose (Knodell); intensidade do depósito de colágeno (coloração pelo picrosirius) e o grau de ativação das células estreladas (marcação com alfa-actina de músculo liso). Os índices destas variáveis histológicas, pós e pré-tratamento, foram relacionadas com o resultado do teste qualitativo RNA HCV (RT-PCR-AMPLICOR?) na 24a semana de tratamento, com a duração do tratamento da hepatite C e com o intervalo de tempo entre a interrupção do tratamento e a biópsia-controle. Foi avaliada a relação de possíveis fatores prognósticos de resposta virológica com a resposta histológica e foram realizadas correlações dos parâmetros histológicos entre si. Resultados: Os parâmetros histológicos avaliados de forma global foram semelhantes nas biópsias pré e pós-tratamento. As razões pós/pré-tratamento, em todos os parâmetros avaliados nas biópsias hepáticas, diminuíram de forma significativa nos pacientes que apresentaram pesquisa negativa para o RNA HCV na 24ª semana de tratamento. Os parâmetros histológicos foram semelhantes nos grupos com duração de tratamentos diferentes (? 24 semanas e > 24 semanas), exceto as CEH células ?-positivas, que teve melhora no grupo com tratamento mais prolongado. O intervalo de tempo entre o final do tratamento e a biópsia-controle não influenciou a melhora histológica. Na análise de regressão logística, houve associação da melhora dos parâmetros histológicos com o resultado negativo do RNA HCV na 24ª semana de tratamento. Houve correlação significativa entre todos os parâmetros histológicos avaliados. Conclusões: Os pacientes avaliados em conjunto tiveram seus parâmetros histológicos nas biópsias pré e pós-tratamento com valores semelhantes, porém quando se definiu melhora histológica, como a manutenção, ou melhora dos parâmetros histológicos avaliados individualmente, verificou-se que uma substancial parcela da população estudada apresentou melhora histológica. O efeito benéfico do tratamento parece se relacionar com o controle da viremia do HCV durante o tratamento e se verifica também em pacientes que não sustentaram a resposta virológica após a suspensão dos medicamentos. Os achados fazem supor que a redução da viremia do HCV teria como conseqüência a diminuição da inflamação e fibrose hepáticas, inclusive com diminuição do estado de ativação das células estreladas hepáticas, mesmo nos casos em que não houve resposta virológica sustentada. Os resultados do presente estudo são sugestivos de que o tratamento da hepatite C pode modificar a história natural da evolução da hepatite crônica nos pacientes co-infectados pelo HIV.
Human immunodeficiency virus (HIV) is known to be able to modify the natural history of HCV infection, accelerating the progression of hepatic fibrosis and the consequent evolution to cirrhosis. Treatment with interferon-alpha can lead to improved hepatic histology, reducing inflammation and fibrosis, especially in patients who present a sustained virologic response. The impact of treatment on histological evolution in patients who do not respond to treatment of hepatitis C is a controversial matter. Objectives: To evaluate in patients with chronic hepatitis C co-infected with HIV the impact of treatment of hepatitis C on the modifications of the parameters indicative of fibrosis and of inflammatory activity in liver biopsies obtained before and after treatment of hepatitis C. Methods: Twenty-six patients co-infected with HCV and HIV-1 were submitted to a liver biopsy before and, on average, 25.2 months after the end of treatment of hepatitis C. Fragments of the liver biopsy were compared before and after treatment regarding the following parameters: histological activity index (HAI) and grade of fibrosis (Knodell); intensity of collagen deposition (picrosirius staining), and grade of stellate cell activation (labeling with smooth muscle alpha-actin). The post- and pretreatment ratios of these histological variables were related to the result of the quantitative HCV-RNA test (RT-PCR-AMPLICOR?) during the 24th week of treatment, to the duration of treatment of hepatitis C and to the time interval between the discontinuation of treatment and the control biopsy. The relationship between possible factors of the virologic response and the histological response was evaluated and correlations between the various histological parameters were calculated. Results: The histological parameters evaluated in a global manner were similar in the pre- and post-treatment biopsies. The post-pretreatment ratios for all parameters evaluated in the liver biopsies were significantly reduced in patients who were negative for HCV RNA during the 24th week of treatment. The histological parameters were similar in the groups with different durations of treatment (? 24 weeks and > 24 weeks), except for ?-positive stellate hepatic cells, which were improved in the group with a more prolonged treatment. The time interval between the end of treatment and the control biopsy did not affect the histological improvement. In logistic regression analysis, the improvement of the histological parameters was found to be associated with a negative result of HCV RNA during the 24th week of treatment. There was a significant correlation between all histological parameters evaluated. Conclusions: When evaluated as a whole, the patients showed similar values for their histological parameters in the pre- and post-treatment biopsies. However, when histological improvement was defined as the maintenance or improvement of the histological parameters evaluated individually, a substantial part of the study population was found to present histological improvement. The beneficial effect of treatment seemed to be related to the control of HCV viremia during treatment and was also observed in patients who did not sustain the virologic response after the discontinuation of the medications. These findings lead us to assume that the reduction of HCV viremia causes a reduction of hepatic inflammation and fibrosis, as well as a reduction of the state of activation of stellate hepatic cells even in cases in which there is no sustained virologic response. The results of the present study suggest that treatment of hepatitis C can modify the natural history of the course of chronic hepatitis in patients co-infected with HIV.

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Bradshaw, Daniel Mark. "Defining risk factors and mechanisms of permucosal transmission of HCV amongst HIV-infected men who have sex with men". Thesis, University of Cambridge, 2016. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.709469.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Rodrigues, Marcus Paulo da Silva. "Custo efetividade do uso do Peguinterferon alfa 2a combinado com Ribavirina no tratamento de respondedores virológicos lentos coinfectados com VHC/HIV". Universidade do Estado do Rio de Janeiro, 2012. http://www.bdtd.uerj.br/tde_busca/arquivo.php?codArquivo=4811.

Texto completo da fonte

Resumo:

No mundo, as hepatites decorrentes de infecções virais têm sido uma das grandes preocupações em saúde pública devido a seu caráter crônico, curso assintomático e pela sua capacidade de determinar a perda da função hepática. Com o uso em larga escala de medicamentos antirretrovirais, a doença hepática relacionada à infecção pelo vírus da hepatite C (VHC) contribuiu para uma mudança radical na história natural da infecção pelo vírus da imunodeficiência humana (HIV). Não se sabe ao certo o peso da coinfecção VHC/HIV no Brasil, mas evidências apontam que independentemente da região geográfica, esses indivíduos apresentam maiores dificuldades em eliminar o VHC após o tratamento farmacológico, quando comparados a monoinfectados. No âmbito do SUS, o tratamento antiviral padrão para portadores do genótipo 1 do VHC e do HIV é a administração de peguinterferon associado à Ribavirina. Quanto ao período de tratamento e aos indivíduos que devem ser incluídos, os dois protocolos terapêuticos mais recentes possuem divergências. A diretriz mais atual preconiza o tratamento de indivíduos respondedores precoces somados a respondedores virológicos lentos, enquanto a diretriz imediatamente anterior exclui na 12 semana indivíduos que não respondem completamente. Com base nessa divergência, esse estudo objetivou avaliar o custo-efetividade do tratamento contra o VHC em indivíduos portadores do genótipo 1, coinfectados com o HIV, virgens de tratamento antiviral, não cirróticos e imunologicamente estabilizados, submetidos às regras de tratamento antiviral estabelecidos pelas duas mais recentes diretrizes terapêuticas direcionadas ao atendimento pelo SUS. Para tal, foi elaborado um modelo matemático de decisão, baseado em cadeias de Markov, que simulou a progressão da doença hepática mediante o tratamento e não tratamento. Foi acompanhada uma coorte hipotética de mil indivíduos homens, maiores de 40 anos. Adotou-se a perspectiva do Sistema Único de Saúde, horizonte temporal de 30 anos e taxa de desconto de 5% para os custos e consequências clínicas. A extensão do tratamento para respondedores lentos proporcionou incremento de 0,28 anos de vida ajustados por qualidade (QALY), de 7% de sobrevida e aumento de 60% no número de indivíduos que eliminaram o VHC. Além dos esperados benefícios em eficácia, a inclusão de respondedores virológicos lentos mostrou-se uma estratégia custo-efetiva ao alcançar um incremental de custo efetividade de R$ 44.171/QALY, valor abaixo do limiar de aceitabilidade proposto pela Organização Mundial da Saúde OMS - (R$ 63.756,00/QALY). A análise de sensibilidade demonstrou que as possíveis incertezas contidas no modelo são incapazes de alterar o resultado final, evidenciando, assim, a robustez da análise. A inclusão de indivíduos coinfectados VHC/HIV respondedores virológicos lentos no protocolo de tratamento apresenta-se, do ponto de vista fármaco-econômico, como uma estratégia com relação de custoefetividade favorável para o Sistema Único de Saúde. Sua adoção é perfeitamente compatível com a perspectiva do sistema, ao retornar melhores resultados em saúdeassociados a custos abaixo de um teto orçamentário aceitável, e com o da sociedade, ao evitar em maior grau, complicações e internações quando comparado à não inclusão.
Worldwide, hepatitis caused by viral infections has been a major concern for public health because of its chronicity, asymptomatic course and its ability to determine the loss of liver function. With the widespread use of antiretroviral drugs, liver disease related to infection with hepatitis C virus (HCV) contributed to a radical change in the natural history of infection with human immunodeficiency virus (HIV). No one knows for sure the weight of coinfection HCV/HIV in Brazil, but evidence suggests that, regardless of geographic region, these individuals have greater difficulty in eliminating HCV compared to monoinfected. In the Brazilian Unified Health System (SUS), the standard antiviral treatment for patients infected with genotype 1 HCV and HIV is the association of pegylated interferon with ribavirin. Regarding the treatment period and which individuals should treat the two most recent protocols have disagreements. The most current protocol calls for treatment of early responders individuals added to slow responders. Since the guideline immediately preceding the 12th week excludes individuals who do not respond completely. Based on this difference, this study aimed to evaluate the costeffectiveness of HCV treatment in individuals with the genotype 1 coinfected with HIV, antiviral-naïve, non-cirrhotic and immunologically stable, undergoing antiviral treatment rules established by two most recent therapeutic guidelines directed to attend by SUS. To this evaluation, was developed a mathematical model of decision, based on Markov chains, simulating the progression of liver disease under treatment and no treatment. It was accompanied by a hypothetical cohort of thousand men individuals, more than 40 years. Was adopted the perspective of the Brazilian Unified Health System, time horizon of 30 years and a discount rate of 5% for the costs and for clinical consequences. The extension of treatment to slow responders provided an increase of 0.28 years of quality-adjusted life (QALY), 7% survival rate and an increase of 60% in the number of individuals who eliminated HCV. Besides the expected benefits in efficacy, the slow viral responders inclusion proved to be a costeffective strategy to achieve an incremental cost-effectiveness of BRL 44,171.00/QALY, value below of acceptability threshold proposed by the World Health Organization (BRL 63,756.00/QALY). Sensitivity analysis demonstrated that the potentials uncertainties in the model are unable to alter the final result, thus demonstrating the robustness of the analysis. The Inclusion of HCV/HIV co-infected individuals slow virologic responders to treatment protocol, is presented from the point of pharmacoeconomic view, as a strategy to cost-effectiveness favorable for the Brazilian Health System. Its adoption is perfectly compatible with the system perspective, returning better health outcomes with costs below an acceptable budget cap, and the society, to avoid a greater extent, complications and hospitalizations when compared to non-inclusion.

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Northfield, John. "Aspects to T-cell phenotype during infection with HIV, CMV and Hepatitis C virus". Thesis, University of Oxford, 2008. http://ora.ox.ac.uk/objects/uuid:283098ce-e24d-4099-8826-07dcc75381f2.

Texto completo da fonte

Resumo:

This work concerns itself with understanding the organisation of cellular immune responses to three major human pathogens - HIV, CMV and Hepatitis C (HCV). Each was studied to form three projects, each undertaken with a different approach - arrived at independently - and largely owing their origins to opportunity and circumstance as much as design. Each project led to exploration of a particular aspect of T-cell phenotype (that is the expression of particular molecular markers on T-cells) and its’ broader biological significance. I found that T-cell phenotype was strongly linked to the magnitude of T-cell responses (CMV) and the ability of T-cells to control infection (HIV). Finally I explored the significance of expression of a molecule known as CD161 on the surface of HCV specific CD8+ T-cells, indicating a phenotype of T-cell that may not follow the ‘normal rules’ applicable to T-cells in general.

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Masembe, Melissa. "The effectiveness of the Stockholm needle exchange programme : Does the Stockholm needle exchange programme control HIV, Hepatitis B, and Hepatitis C in intravenous drug users?" Thesis, Södertörns högskola, Institutionen för naturvetenskap, miljö och teknik, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:sh:diva-38802.

Texto completo da fonte

Resumo:

BACKGROUND: The needle exchange programme (NEP) started in Sweden in 1986 in Lund and shortly after in Malmo. The first NEP in Stockholm opened in spring 2013. The NEP is a service aimed at intravenous drug users (IDU) from 18 years old, with a goal of preventing the blood borne diseases, such as HIV, Hepatitis B (HBV), and Hepatitis C (HCV). With the on going HIV and Hepatitis epidemics, numerous countries around the world have adopted control strategies, such as the NEP to halt the spread of HIV, HBV, and HCV. The objective of this study was to examine if the needle exchange programme has decreased the incidence of HIV, HBV, and HCV in Sweden over a six-year period. METHODS: Data for incidence and prevalence was extracted from the yearly reports of the Stockholm’s needle exchange programme from 2013 to 2018 and the yearly reports of the public health agency in Sweden from 2013 to 2018. The data was collected for Stockholm, and compared to Västra Götaland, and the whole of Sweden. RESULTS: The incidence of HIV was zero in 2013 and 2015 in the NEP. The incidence of HBV decreased to zero in 2013 in the NEP. There is an increased incidence of HCV in the NEP. CONCLUSION: The NEP has a protective effect through its combination of needle exchange, opiate substitute therapy, counselling, and vaccinations in reducing and stabilising incidences of the infections, in some instances to zero, as well as providing surveillance and treating infections.

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

Maerrawi, Ilham El. "Desenvolvimento de um estudo piloto de uma pesquisa que visa identificar fatores de risco associados às infecções pelo HIV, hepatites B, C e sífilis em população carcerária". Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/5/5137/tde-09122009-174537/.

Texto completo da fonte

Resumo:

Introdução: A população confinada é um segmento exposto a certas situações que aumentam sua vulnerabilidade frente às doenças sexualmente transmissíveis. Infecções pelo HIV, hepatites B e C e sífilis encontram no sistema prisional um ambiente favorável às suas propagações. Estudos em população confinada são cercados de entraves tanto burocráticos como relacionados com a ética e segurança. Assim, assume grande importância um estudo - piloto para, entre outras coisas, identificar pontos prós e contras que possam surgir durante a execução do estudo principal. Objetivo: Desenvolver um estudo piloto para uma pesquisa sobre fatores de risco comportamentais referentes à contaminação pelas infecções pelo HIV, hepatites B e C e sífilis numa população carcerária. Métodos: Estudo epidemiológico transversal. Em julho de 2007, numa amostra de conveniência, 107 reeducandos foram estrevistados usando um questionário padrão e tecnica face-face. O estudo foi aprovado pelo Comitê de Ética em Pesquisa do HCFMUSP. Resultados: Foram realizadas todas as etapas planejadas, a saber: Reuniões na unidade: entre a direção e diversas equipes da unidade prisional; Convite aos participantes: contato com representantes dos reeducandos; Assinatura do TCLE: após formalização do convite à participação do estudo e Aplicação do questionário. Realizadas reuniões sistemáticas para ajuste do questionário. Feita a capacitação de entrevistadores. Elaborado um banco de dados no Microsoft Office para receber os dados por meio de dupla digitação. Foram entrevistados 16,5% da população da unidade. Apresentaram um perfil jovem com média de 31,1 anos de idade. O tempo médio de prisão foi de 18,7 meses. A idade média de início de uso de drogas legais foi de 14,7 e ilegais de 16,6 anos. Após o confinamento, houve redução no consumo de drogas e sem relatado de droga injetável no presídio. 55,1% realizaram tatuagem na prisão. 41,2% relataram ocorrência de DST na vida e 34,0% no ultimo mês, 2,5% referiram serem soropositivos para o HIV. 53,8% mantiveram o numero de relações sexuais após o confinamento e dos 28,6% que faziam uso sistemático de preservativos, 26,3% mantiveram esta freqüência no presídio. Envolvidos com agressões: 78,5% verbais e 65,1% físicas, sendo que 33,6% referiram ameaças de morte. Maconha, álcool e crack foram as drogas envolvidas nestas situações. Discussão: O estudo piloto possibilitou testar o instrumento de pesquisa, sua aplicabilidade e capacidade de identificar fatores de riscos para transmissão das infecções citadas, tanto fora quanto dentro do ambiente prisional. O treinamento dos entrevistadores favoreceu tanto a familiarização com o instrumento, quanto o contato adequado ético e seguro - com os reeducandos. A vivência com esta realidade contribuiu para mapear pontos vulneráveis do planejamento para a execução do estudo principal. Limites do estudo: As análises e a obtenção da sorologia não faziam parte do estudo piloto, postergadas para o estudo principal com amostra adequada. Questionários, quando utilizados como instrumento de coleta, podem apresentar problemas relacionados com as informações obtidas. Muitas delas podem não condizer com a realidade, tanto de forma proposital viés de informação quanto de forma não proposital viés de memória.
Introduction: Confined populations are exposed to circumstances that increase their vulnerability to sexually transmitted infections. HIV, hepatitis B and C, and syphilis, encounter at the prison system an environment favorable to their dissemination. Studies in confined populations are surrounded by bureaucratic, ethical and security barriers. Thus, a pilot study is of great importance -for identify obstacles and opportunities that may arise during the implementation of the main study. Objective: implementation of a pilot study on risk behaviors associated to the dissemination of HIV, hepatitis B and C, and syphilis in an incarcerated population. Methods: Cross Sectional study. In July of 2007, in a convenience sample, 107 prisoners were interviewed, face to face, using a standardized questioner. The study was approved by the Human Subject Committee of the Hospital das Clinicas of the School of Medicine from the University of Sao Paulo. Results: the research protocol was strict followed: institutional meetings of the direction and the different professional teams of the prison system; invitation to participants in close contact with prisoners representatives; signature of the consenting forms after the invitation and before the questionnaire was applied. Meetings were conducted to adjust the questionnaire. Interviewers were trained. A dataset using Microsoft Office was elaborated to allow insertion of the data collected. Subjects represented 16, 5% of the prison population. Participants were young, average of 31, 1 years of age. The length time in prison was 18, 7 months in average. The average of the initiation in the use of legal drugs was 14, 7 and illegal drugs 16, 6 years of age. After the arrestment there was a diminishment of the use of drugs, and no injection of drugs was reported. Tattoo inside of the prison was reported by 55, 1%. STI were reported by 41, 2% in life and by 34% in the last month, and 2, 5% reported to be HIV positive. 53, 8% maintained the same amount of sexual relation that they had outside of the prison. From the 28, 6% that regularly used condoms, 26, 3 regularly used inside of the prison too. Interviewed that were involved in aggression were 78, 5% verbal and 65, 1% physic, and 33, 6% refereed being threatened of dead. Marijuana, Alcohol and crack were the drugs involved in such circumstances. Discussion: The pilot study has tested the instrument of research, its applicability and ability to identify risk factors for transmission of the mentioned infections, both within or outside of the prison. The training of interviewers favored both the familiarity with the instrument, as the appropriate contact secure and ethical - with inmates. The experience with this reality has contributed to map vulnerabilities in the implementation of the main study. Limitations of the study: serology and analysis were not part of the pilot study, therefore postponed for the main study with adequate sample. Questionnaires may present problems with the information obtained. Many of the information may not match the reality; both, information or memory biases could be identified.

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

Farías, Adrián Alejandro. "Hepatitis C en Córdoba: Implicancias de la coinfección HIV/HCV y cambios locales en el perfil epidemiológico molecular". Doctoral thesis, Farías AA. Hepatitis C en Córdoba: Implicancias de la coinfección HIV/HCV y cambios locales en el perfil epidemiológico molecular [Internet]. Universidad Nacional de Córdoba, 2013 [citado el 13 de febrero de 2020]. Disponible en: https://rdu.unc.edu.ar/handle/11086/6732, 2013. http://hdl.handle.net/11086/6732.

Texto completo da fonte

Resumo:

Tesis - Doctor en Ciencias de la Salud - Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Secretaría de Graduados en Ciencias de la Salud, 2013
139 h. : il., 29 cm.
The hepatitis C virus (HCV) is considered one of the major causes of chronic hepatitis, cirrhosis and liver cancer. Co-infection with HIV accelerates the progression of liver disease, increases the efficiency of transmission of HCV by non-parental routes and has been associated with the decrease in the effectiveness of HAART. Worldwide, HCV distribution and its molecular pattern are markedly heterogeneous and are continuously changing, due to cultural changes, associated to new risk behaviors, as well as population movements. The aim of this work was to study the prevalence and genetic diversity of HCV infection in HIV co-infected individuals of Córdoba, evaluate its influence on antiretroviral therapy (HAART) and in HCV transmission, and identify possible changes in HCV genotype distribution pattern of Córdoba in the last 10 years. This study included the following samples obtained from patients of Córdoba: a) 349 serum samples from chronically infected individuals collected between 1999-2009; b) 86 serum samples from HCV/HIV co-infected patients obtained from a total of 558 HIV+ patients, collected in 2 periods between 2003-2007; and c) 37 biological fluid samples of HCV moninfected (n=21) and HCV/HIV co-infected individuals (n=16) [cervical swab (n=16), saliva (n=37), seminal plasma (n=21) and peripheral blood mononuclear cells (n=37)]. RT-nested PCR of the 5’ non-coding region (5’ NC) was used for HCV molecular detection. For genomic characterization and subsequent phylogenetic and viral evolution analysis, non-structural 5B and E1/E2 genomic regions were amplified and sequenced.
El virus de la Hepatitis C es considerado una de las principales causas de hepatitis crónica, cirrosis hepática y cáncer hepático. La coinfección con HIV acelera la progresión de la enfermedad hepática, aumenta la efectividad de la transmisión de HCV por vías no parenterales y ha sido asociada a la disminución de la efectividad de la terapia HAART. A nivel mundial, la distribución y el patrón molecular de HCV son marcadamente heterogéneos y se modifican continuamente debido tanto a cambios culturales, asociados a nuevas conductas de riesgo, como a movimientos poblacionales. El objetivo del presente trabajo fue estudiar la prevalencia y la diversidad genética de la infección por HCV en individuos coinfectados con HIV de Córdoba, evaluar su influencia en la terapia antiretroviral (HAART) y en la transmisión de HCV, y detectar posibles cambios en el patrón regional de distribución de genotipos en los últimos 10 años. En este estudio se incluyeron las siguientes muestras obtenidas de pacientes de Córdoba: a) 349 muestras de suero obtenidas de individuos crónicamente infectados por HCV colectados entre 1999-2009; b) 86 sueros de pacientes coinfectados HCV/HIV obtenidos de un total de 558 pacientes HIV+, colectados en dos periodos entre 2003-2007; y c) 37 muestras de fluidos biológicos de pacientes monoinfectados (n=21) y coinfectados HCV/HIV (n=16) [hisopado cervical (n=16), saliva (n=37), plasma seminal (n=21) y células mononucleares de sangre periférica (n=37)]. Para la detección molecular de HCV se utilizó RT-nested PCR de la región 5’ no codificante (5’ NC), y para la caracterización genómica y posterior análisis filogenético y evolución viral, se amplificaron y secuenciaron las regiones no estructural 5B y E1/E2.
Fil: Farías, Adrián Alejandro. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas Instituto de Virología Dr. José María Vanella; Argentina.

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

Sinclair, Michael. "A qualitative exploration of coping and adhering with hepatitis C treatment amongst a cohort of gay men in London co-infected with HIV and hepatitis C". Thesis, University of Essex, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.435559.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Bó, Andréa Gurgel Batista Leite Dal. "Avaliação da progressão da fibrose hepática em adultos coinfectados pelo vírus HIV e da hepatite C por meio de biópsias hepáticas pareadas". Universidade de São Paulo, 2012. http://www.teses.usp.br/teses/disponiveis/5/5134/tde-01032013-134648/.

Texto completo da fonte

Resumo:

INTRODUÇÃO: Pacientes com coinfecção HIV e hepatite C, em geral, apresentam rápida progressão da fibrose hepática. No entanto, a maior parte dos estudos, que avaliam essa questão, caracteriza a progressão da fibrose de forma indireta, utilizando para isso uma única biópsia hepática e tendo como base de cálculo o tempo estimado de infecção pelo vírus da hepatite C. OBJETIVO: Os objetivos do presente trabalho são: 1-Estimar a taxa de progressão da fibrose hepática de forma direta, através da análise de biópsias pareadas em pacientes coinfectados HIVhepatite C, não submetidos a tratamento prévio para hepatite C; 2- Avaliar a possível associação dessa progressão a determinadas variáveis clínicas. MÉTODOS: Trinta pacientes coinfectados com HIV e hepatite C, sem antecedente de tratamento prévio da hepatite C, submetidos a duas biópsias hepáticas pareadas foram avaliados. Calculou-se a taxa de progressão de fibrose direta e foram feitas determinações de progressão, estabilização e regressão da fibrose. Procedeu-se então à análise estatística, testando-se a associação entre progressão de fibrose e algumas variáveis clínicas e demográficas. RESULTADOS: A taxa de progressão média foi de 0,13 UF/ano, com 36,7% dos pacientes configurando-se como progressores. Em análise univariada, a progressão de fibrose hepática esteve associada a níveis de alanina aminotransferase (p<0,001) e aspartato aminotransferase (p<0,0340) acima de 3 vezes o limite superior da normalidade à época da primeira biópsia. Verificou-se também associação entre níveis de alanina aminotransferase (p=0,049) e aspartato aminotransferase (p=0,013) acima da normalidade e atividade necroinflamatória à primeira biópsia. CONCLUSÕES: Elevações de alanina aminotransferase e aspartato aminotransferase parecem estar associadas a uma maior atividade necroinflamatória em pacientes co-infectados pelo HIV e hepatite C e também a uma progressão mais acelerada da fibrose hepática nesse grupo de pacientes
INTRODUCTION: HIV and hepatitis C virus co-infected patients usually exhibit rapid liver fibrosis progression. However, most studies evaluating this issue indirectly characterize fibrosis progression via single liver biopsy, further using this as basis for calculating the estimated duration of hepatitis C infection. OBJECTIVE: Objectives of this study include: 1- Estimate the annual rate of direct liver fibrosis progression, using analyses of paired biopsy samples from HIVhepatitis C co-infected patients without prior treatment for hepatitis C; 2- Assess the possible association of fibrosis progression with certain clinical variables. METHODS: We evaluated 30 HIV-hepatitis C co-infected patients, with no history of prior treatment for hepatitis C, who underwent two paired liver biopsies. We calculated the annual rate of direct fibrosis progression and determined fibrosis progression, stabilization, and regression. We then performed statistical analysis, testing the association between fibrosis progression and several clinical and demographic variables. RESULTS: The average annual progression rate was 0.13 FU/year, with 36.7% of patients defined as progressors. In univariate analysis, liver fibrosis progression was associated with alanine aminotransferase (p<0.001) and aspartate aminotransferase (p<0.0340) levels over three times the upper limit of normal present at first biopsy. There was also an association between above-normal alanine aminotransferase (p=0.049) and aspartate aminotransferase (p=0.013) levels and necroinflammatory activity at first biopsy. CONCLUSION: Elevated alanine aminotransferase and aspartate aminotransferase levels appear to be associated with higher necroinflammatory activity and more accelerated liver fibrosis progression among HIV-hepatitis C co-infected patients

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Silva, Synara Alexandre Araujo. "Desenvolvimento de uma técnica molecular para detecção e quantificação do vírus da hepatite G (GBV-C/HGV)". Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/5/5134/tde-22062010-123341/.

Texto completo da fonte

Resumo:

Introdução: O vírus da hepatite G (GBV-C/HGV) é um flavivírus de genoma RNA de fita simples polaridade positiva, replicando em linfócitos, não sendo até hoje associado a qualquer patogenia humana. Estudos recentes demonstram que pessoas co-infectadas pelos vírus GBV-C/HGV e HIV têm menor progressão para AIDS e morte, embora alguns estudos tenham falhado em demonstrar tais efeitos. Objetivo: Determinar a soroprevalência e viremia (qualitativa) por GBV-C/HGV nas amostras de pacientes HIV+ e desenvolver uma metodologia de PCR em tempo real para fazer a determinação das cargas virais de GBV-C/HGV. Métodos: Avaliamos a presença de anticorpo e RNA do vírus GBV-C/HGV em 253 amostras de plasma de mulheres HIV positivas, coletadas entre 1997-99. Realizamos o ensaio imunoenzimático anti-E2 (EIA anti-HGenv kit, Roche(TM)), a reação em cadeia da polimerase (PCR), o NESTED PCR e, padronizamos um PCR em tempo real (RT-PCR), ensaio baseado no sistema Taqman, também aplicado nas mesmas amostras. A curva-padrão do ensaio foi feita com diluições seriadas de uma bolsa de plasma GBV-C/HGV+, e os resultados expressos em unidades aleatórias/mL. Resultados: Das 253 amostras testadas, 64 foram positivas para o anticorpo anti-E2 (25,3%), 36 RNA positivas no PCR convencional (14,2%) e, no NESTED PCR e PCR em tempo real 57 amostras foram concordantemente RNA positivas (22,5%), perfazendo um índice total de exposição de 48% (25.3 + 22.5). A carga viral teve uma média de 1.396 UA/mL (13.625 - 1.1UA/mL. As cargas virais encontradas não tiveram correlação direta com parâmetros laboratoriais da infecção pelo HIV como a carga viral e a contagem de células CD4. Conclusões: Foi obtida uma metodologia simples, rápida e de boa sensibilidade e especificidade, permitindo a quantificação do RNA do vírus GBV-C com reprodutibilidade. A metodologia permite análise simultânea de um grande número de amostras, sendo apropriada para estudos clínicos. A prevalência de exposição á este agente na população feminina HIV+ estudada é alta, provavelmente decorrente da via sexual comum de transmissão dos agentes.
Introduction: The Hepatitis G (GBV-C / HGV) agent is a flavivirus. Its genome is composed of single stranded RNA of positive polarity, replicating in lymphocytes. Up to now, it hasn\'t been implicated in any disease associated to human beings. Recent studies demonstrate that persons co-infected by the viruses GBV-C / HGV and HIV have a slower rate of progression to AIDS and death, although some studies have failed in demonstrating such effects. Objective: To determine the soroprevalence and viremia (qualitative) of GBV-C / HGV in samples from HIV-infected women. To develop a methodology of Real-Time PCR for GBV-C / HGV viral load determination. Methods: The presence of antibody and GBV-C/HGV RNA was evaluated in 253 plasma samples from HIV infected women, collected between 1997-99. An immunoenzymatic assay (EIA kit for anti-E2, Roche(TM)) was applied to obtain the seroprevalence while the polymerase chain reaction (PCR), nested PCR, and a standardized Taqman based real-time PCR (RT-PCR), were used in the assessment of viral RNA. For the viral load, a standard-curve was made with serial dilutions of a plasma bag containing GBV-C/ HGV RNA+, and results were expressed in random units/mL, in comparison to the reference matherial. Results: Of the 253 samples tested, 64 were positive for anti-E2 (25.3%), 36 RNA positive by PCR (14.2%), and 57 (22.5%) where both nested PCR and real-time PCR RNA positive, for a total exposure index of 48%. The mean viral load was of 1.396 RU/mL (13.625 - 1.1 RU/mL). GBV-C/HGV Viremia was not correlated to HIV laboratorial parameters, i.e. CD4 and HIV-RNA counts. Conclusions: A simple, fast and efficient system for the determination of GBV-C/HGV viral load was developed, presenting appropriate sensitivity and specificity, allowing reproducible quantification of GBV-C RNA in stored plasma samples. The methodology allows simultaneous analysis of a large number of samples, being appropriate for clinical studies. The prevalence of exposition to this agent in the studied female population is high, probably a consequence of the common sexual way of transmission of the agents.

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

Soares, Celina Maria Pereira de Moraes. "Soroprevalência das hepatites B e C, CRAIDS, Santos - 2004/2005". Universidade Católica de Santos, 2006. http://biblioteca.unisantos.br:8181/handle/tede/593.

Texto completo da fonte

Resumo:

Made available in DSpace on 2015-02-04T21:42:14Z (GMT). No. of bitstreams: 1 Celina Soares.pdf: 585127 bytes, checksum: dbb978516e57361340a9d4e0b3953a00 (MD5) Previous issue date: 2006-04-27
Esta pesquisa é um estudo transversal, com método quantitativo e análise de prevalência dos dados. Apresenta como objetivo estimar a soroprevalência das hepatites virais B e C em pacientes infectados pelo HIV. A justificativa deste estudo evidencia-se nas atuais doenças sexualmente transmissíveis (HIV e HBV) e de transmissão sanguínea (HIV, HBV e HCV), por protagonizar substancialmente o panorama do enfrentamento mundial em saúde pública. Santos/SP, cidade litorânea e turística, onde está localizado o maior porto marítimo da América Latina, com um grande número de homens que fazem sexo com homens, mulheres trabalhadores do sexo e usuários de drogas injetáveis, além de apresentar população flutuante de turistas, trabalhadores diretos e indiretos na atividade portuária. Neste sentido constrói um perfil humano relevante que caracteriza a elaboração do atual estudo. A coleta de dados foi realizada na população de pacientes matriculados no Centro de Referência em Aids CRAIDS, Santos, SP. A amostra foi constituída por 1438 pessoas, no período de fevereiro de 2004 a fevereiro de 2005. A análise nos prontuários foi realizada selecionando resultados de marcadores sorológicos para as hepatite B (HBsAg e anti-HBs) e hepatite C (anti-HCV), pela técnica de ELISA, além dos exames sorológicos de menor contagem de linfócitos T CD4+ e maior contagem de carga viral para o HIV, considerando as variáveis: sexo, idade, escolaridade, estado civil, forma de contaminação. Os resultados demonstraram que na população dos 1438 indivíduos HIV+, 54.6% eram do sexo masculino e 45.4% do feminino. Em relação à idade, 71% estavam entre 30 e 49 anos e 54.3% com nível de escolaridade no ensino fundamental. A contagem de linfócitos CD4+ revelou 43.7% com níveis abaixo de 200 células /mm³. Considerando a soroprevalência dos marcadores HBsAg, anti-HBs, Anti-HCV e fatores de risco para essas doenças obtivemos uma prevalência global de HBsAg de 7.4% e 23.5% para o anti-HCV. As variáveis que apresentaram associação com o HBV foram: idade, baixos níveis de células T CD4+, homossexualidade masculina e UDI; para HCV: idade, sexo, escolaridade de nível superior e UDI.

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

King, S. "An investigation into the genetic variation of hepatitis C virus in patients coinfected with HIV". Thesis, University of Liverpool, 2015. http://livrepository.liverpool.ac.uk/2052665/.

Texto completo da fonte

Resumo:

Co-infection with HIV in patients with chronic HCV infection is a common occurrence, which accelerates disease progression and the rate of liver fibrosis. Current literature report conflicting results on the effect of HIV co-infection on HCV at the genetic level. This thesis sets out to further explore the genetic variation of HCV in this group of patients, and use new techniques which may impact upon the diagnosis and management of HCV. In resource-limited settings such as sub-Saharan Africa, there is a paucity of data concerning rates of active HCV infection in patients with HIV infection. The limited infrastructure and financial restrictions are contributing factors in this. Consequently, cheaper and novel diagnostic procedures are required to promote testing in these important cohorts. A real-time PCR assay for use with pooled plasma and dried plasma spot specimens was developed to screen a large cohort of HIV-infected individuals from Ghana and assess its suitability for screening in such a setting. The prevalence of active HCV infection in this cohort was similar to previous estimates from blood donors but was much lower than estimates from serological tests, highlighting the potential risks in relying on these tests alone in this region. The diversity of strains found within this population agreed well with previous studies. As the yield of HCV infections was low in Ghana, further studies were completed with the UK and European cohort. A deep sequencing approach was utilised to two effects. The first focussed on a specific notable polymorphism – Q80K in the NS3 gene – to determine whether deep sequencing would benefit the clinic in the detection of this polymorphism at low frequencies, which are below the threshold of detection by traditional population sequencing. The second use of deep sequencing aimed to determine the impact of HIV co-infection on the presence of resistance associated mutations occurring at baseline, studying the largest cohort to date. The Q80K polymorphism was not observed in any sample as a minority variant, suggesting that the current clinical procedures for pre-treatment screening are suitable and provide sufficient sensitivity. Overall, resistance mutations were relatively common among patients and it was observed that, generally, there were no differences in the prevalences of resistance mutations between HCV mono-infected and HIV/HCV co-infected patients. This finding is in agreement with previous small-scale studies. This work has direct clinical implications on the use of deep sequencing for screening patients for the presence of resistance mutations. Furthermore, it suggests that co-infected individuals are not at risk of further complications for the treatment of HCV.

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Gogela, Neliswa Antonia. "Hepatitis C prevalence in HIV infected heterosexual men and men who have sex with men". Master's thesis, University of Cape Town, 2018. http://hdl.handle.net/11427/29567.

Texto completo da fonte

Resumo:

Background: Globally 1% of individuals are infected with hepatitis C virus (HCV). In South Africa (SA), the prevalence ranges between 0.3% - 1% with few prospective screening data available. Similarly, local data on transmission modes of HCV are limited but probably include parenteral routes and pre-1992 blood or blood product products. The risk of heterosexually transmission is low but is increased in men who have sex with men (MSM) with co- transmission risk of both HIV and HCV. Objectives: Given a limited local understanding, we sought to better understand HCV characteristics and prevalence in 2 groups of HIV-infected men. Methods: HIV positive men in the greater Cape Town metropolitan area were recruited. Sexual orientation was self-identified and demographic and other personal data obtained via a confidentially administered questionnaire. Participants were screened for HCV after a blood draw and positive HCV Ab tests were tested for HCV RNA. Risk factors associated with HCV seropositivity were determined. Results: Five hundred HIV positive men were recruited; 215 (43%) non-MSM and 285 (57%) MSM, with median age 36 years (IQR 20 – 64) and 37 years (IQR 21 – 56), in the MSM and non-MSM group, respectively, p = NS. Overall, 3.4% (n=17) screened HCV positive, 5.6% (n=16) MSM and 0.5% (n=1) non-MSM, with 82.4% viremic for HCV RNA. In respect to genotype (GT) distribution, 50% were infected with GT1, 14.3% GT4 and 35.7% were GT2. In terms of risk, MSM were more likely to have used drugs (54.4% vs. 30.2%, p<0.001) and to have used all five modes of drugs administration (13% of MSM vs. 0.5% of non- MSM for injected drugs, 36.1% vs. 2.3% inhaled, 10% vs. 0% for the rectal route, 48.1% vs. 28.8% for smoked and 27.4% vs. 2.3% for oral drugs). More MSM than non-MSM (46.3% vs. 16.7%) reported sex whilst using recreational drugs and similarly more MSM (21.4% vs. 14%) reported having sex with a sex worker (SW).Risk factors for HCV seropositivity included drug use history (odds ratio (OR) 6.28, 98% confidence interval (CI). 1.78 – 22.12: p=0.004) and in MSM, sex with SW (OR 5.5, 95% 2.06 – 14.68; p=0.001) or use of recreational drugs with sex (OR 6.88, 95% CI 2.21 -21.44; p=0.001). Conclusion: HCV prevalence in HIV positive MSM is higher than previously appreciated or documented in South Africa. Risk factors include injecting drug use, use of recreational drugs with sex and sex with SWs. Targeted interventions are required to address this emerging challenge to achieve the viral hepatitis elimination ideal by 2030.

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Neto, Gaspar Lisbôa. "Identificação de polimorfismos e mutações primárias de resistência aos inibidores de protease (NS3/NS4A) no vírus da hepatite C em pacientes com hepatite C crônica monoinfectados e coinfectados pelo vírus da imunodeficiência humana". Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/5/5134/tde-31072017-150758/.

Texto completo da fonte

Resumo:

INTRODUÇÃO: A hepatite C crônica é uma das principais causas de hepatopatia em todo mundo. A coinfecção pelo vírus C (VHC) e o HIV não é incomum, pois ambos compartilham vias similares de transmissão. Recentemente, a terapêutica da hepatite C crônica foi radicalmente modificada com o advento das drogas antivirais de ação direta (DAAs), elevando as taxas de RVS mesmo na população coinfectada. O VHC é caracterizado pela sua alta taxa replicativa e por grande diversidade populacional. Substituições de ocorrência natural na protease viral associadas a resistência podem comprometer a terapêutica em alguns regimes baseados no uso de inibidores de protease (IPs). OBJETIVOS: Estimar a prevalência de polimorfismos e mutações de ocorrência natural associadas a resistência aos IPs em pacientes monoinfectados e coinfectados pelo VHC e HIV e identificar fatores clínicos e virológicos associados a presença de tais substituições. MATERIAIS E MÉTODOS: Dados epidemiológicos e clínicos foram obtidos de 247 pacientes (135 monoinfectados e 112 coinfectados pelo VHC e HIV). VHC RNA foi extraído do plasma dos indivíduos participantes e um fragmento de 765 pares de base da região NS3 foi amplificado e sequenciado por metodologia populacional (técnica de Sanger). O estadiamento da fibrose hepática foi realizado pelo escore não invasivo FIB- 4. RESULTADOS: 54 indivíduos (21,9%) apresentaram pelo menos uma substituição na região NS3/NS4A do VHC. Somente 14 pacientes (5,7%) apresentaram pelo menos uma mutação de resistência aos IPs (T54S, V55A ou Q80R). A Q80K não foi identificada em nenhuma das amostras. Não houve diferença entre monoinfectados e coinfectados quanto à ocorrência de polimorfismos ou mutações associadas a resistência. As variáveis independentemente associadas com substituições na região da protease foram infecção pelo VHC genótipo 1b, bilirrubinas totais > 1,5 vezes o LSN e níveis de albumina < 3,5 g/dL. Fibrose hepática avançada (FIB-4 > 3.25) não esteve associada a presença de substituições. A análise de diversidade nucleotídica na protease viral revelou maior heterogeneidade do VHC genótipo 1b em relação ao 1a. Contudo, a análise de pressão seletiva não demonstrou maior variabilidade de quasiespécies no grupo de hepatopatia avançada, achado este compatível com uma sequência genômica relativamente conservada. CONCLUSÕES: As substituições na região NS3/NS4 do VHC consistiram majoritariamente por polimorfismos naturais sem impacto clínico num eventual tratamento que envolva o uso de IPs. A prevalência de substituições associadas a resistência foi baixa e compatível com os valores informados pela maioria dos estudos nacionais e internacionais. A coinfecção pelo HIV não parece elevar a frequência de substituições na protease do VHC. A região NS3 do genótipo 1b foi altamente variável em relação ao genótipo 1a, reforçando o conceito de possíveis diferenças geográficas em relação ao perfil genético deste vírus
INTRODUCTION: Chronic hepatitis C is a major cause of liver disease worldwide. Hepatitis C vírus (HCV) and HIV coinfection is not uncommon due to similar transmission routes. Recently developed direct-acting antivirals drugs (DAAs) have increased the rate of SVR even in coinfected patients. HCV has a high replication rate and a lack of proofreading activity, leading to a greatly diverse viral population. Baseline spontaneously occurring resistance substitutions in the protease region may impair the rate of success in some protease inhibitors (PI) based regimens. OBJECTIVE: to determine the prevalence of naturally occurring polymorphisms and resistance associated variants to HCV PIs in mono and coinfected HCV HIV patients and to evaluate potential associations between amino acid substitutions in protease domain and clinical / virological features of those patients. METHODS: Clinical and epidemiological data were retrieved from medical records of 247 subjects in Brazil (135 HCV monoinfected and 112 HIV HCV coinfected patients). HCV-RNA was extracted from plasma and a fragment of 765 base pairs from the NS3 region was amplified and sequenced with Sanger-based technology. Fibrosis staging was assessed by non invasive score (FIB-4). RESULTS: Overall, 54 patients (21.9%) had at least one amino acid substitution in the NS3 region; only 14 patients (5.7%) harboured at least one resistance mutation (T54S, V55A, Q80R). Q80K mutation was not found in any sample. There was no difference between monoinfected and coinfected patients regarding the frequency of natural polymorphisms and resistance mutations. Variables independently associated with amino acid substitution were HCV subtype 1b, total bilirubin level > 1.5 ULN and albumin level < 3.5 g/dL. Advanced liver fibrosis (FIB-4 > 3.25) was not related to NS3 polymorphisms nor resistance associated variants. Examination of HCV protease nucleotide diversity revealed greater heterogeneity in subtype 1b than subtype 1a. Analysis of selective pressure did not reveal a greater quasispecies variability in advanced liver fibrosis group, being such finding consistent with a relatively conserved gene in this setting. CONCLUSION: Baseline HCV NS3 amino acid substitutions depicted herein were considered mostly natural polymorphisms with no clinical impact in a PI based therapy. The prevalence of resistance-associated substitutions was low and compatible with values reported by most national and international studies. HIV coinfection was not associated with a greater frequency of such substitutions in the studied sample. The NS3 region of genotype 1b was highly variable in relation to genotype 1a, highlighting geographic differences concerning HCV genetic profile

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

Cabrera, Christine M. "Measurement of Stigma and Relationships Between Stigma, Depression, and Attachment Style Among People with HIV and People with Hepatitis C". Thèse, Université d'Ottawa / University of Ottawa, 2013. http://hdl.handle.net/10393/30348.

Texto completo da fonte

Resumo:

This dissertation is composed of three studies that examined illness-related stigma, depressive symptoms and attachment style among patients living with HIV and Hepatitis C (HCV). The first study examined the psychometric properties of a brief HIV Stigma Scale (B-HSS) in a sample of adult patients living with HIV (PHA) (n=94). The second study developed and explored the psychometric properties of the HCV Stigma Scale in a sample of adult patients living with HCV (PHC) (n =92). Psychometric properties were evaluated with classical test theory and item response theory methodology. The third study explored whether illness-related stigma mediated the relationship between insecure attachment styles (anxious attachment or avoidant attachment) and depressive symptoms among PHA (n =72) and PHC (n=83). From June to December 2008, patients were recruited to participate in a questionnaire study at the outpatient clinics in The Ottawa Hospital. Findings indicated that the 9-item B-HSS is a reliable and valid measure of HIV stigma with items that are highly discriminatory, which indicates that items are highly effective at discriminating patients with different levels of stigma. The 9-item HCV Stigma Scale was also found to be reliable and valid with highly discriminatory items that effectively differentiate PHC. Construct validity for both scales was supported by relationships with theoretically related constructs: depression and quality of life. Among PHA, when HIV stigma was controlled the relationship between anxious attachment style and depression was not significant. However, the relationship between avoidant attachment style and depressive symptoms decreased but remained significant. Among PHC when HCV stigma was controlled the relationship between insecure attachment styles and depressive symptoms was not significant. Dissertation results emphasize the importance of identifying patients experiencing illness-related stigma and the relevance of addressing stigma and attachment style when treating depressive symptoms among PHA and PHC.

Estilos ABNT, Harvard, Vancouver, APA, etc.

Teses / dissertações sobre o tema "HIV/Hepatitis C"

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos